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CHAPTER 1 
INTRODUCTION AND OUTLINE OF 
THE INVESTIGATION 
1.1 INTRODUCTION 
Infertility is defined as a failure to conceive after at least one year of unprotected 
intercourse.1 The common estimation is that around ten percent of the couples are 
infertile if no treatment is given.2 It is difficult to estimate the relative contribution of 
both partners to the infertility. The account to infertility of a female factor may range 
from 44% to 70%, and of a male factor from 21% to 31% as indicated by different 
authors.3-9 Unexplained infertility has been reported to occur with an incidence ranging 
from 6 to 28%. 1 0 It is not always a single factor that contributes to the inability to 
conceive, multifactorial infertility is not uncommon.46 
For different reasons one must realise that the fertility of an individual is relative. 
Fertility and infertility are not always absolute. There is a gradual difference possible 
between the two extremes. The interactions between the fertility potentials of each 
partner determines the ultimate fertility potential of the couple. Furthermore one's 
(in)fertility is not a constant condition, but may change along with time. 
Prior to understanding the problem of infertility, knowledge of the physiological 
mechanisms involved in the regulation of oocyte maturation, ovulation, sperm transport, 
fertilisation and implantation is necessary. 
1.2 GENERAL REVIEW OF THE PHYSIOLOGY OF 
REPRODUCTION 
1.2.1 Fertilisation 
During coitus approximately 200 χ IO6 spermatozoa are deposited on the cervix and 
posterior vaginal fornix. Human semen coagulates immediately following ejaculation, 
but then becomes liquefied by seminal proteolytic enzymes within a few minutes.11 
After liquefaction the spermatozoa are capable to penetrate the cervical mucus. The 
coagulum and the buffering capacity of the seminal plasma protect the spermatozoa 
from the acid environment of the vagina. Cervical secretion also increases the alkalinity 
which is more favourable for spermatozoa. 
Spermatozoa can penetrate cervical mucus by their intrinsic motility, but due to a 
selection process only morphologically normal sperm cells seem to be able to pass the 
cervix.12-16 Roughly one spermatozoon out of thousand is capable of passing the 
1 
cervical barrier and ascend into the uterus. Ovarian hormones, especially oestrogens, 
regulate the secretion and physical properties of cervical mucus. The amount and the 
quality of cervical mucus show cyclic variations. The condition of cervical mucus 
greatly influences sperm receptivity. During the preovulatory period the mucus is most 
receptive to sperm penetration.17·18 
The second barrier spermatozoa have to overcome before reaching the site of fertili-
sation is the uterotubal junction. At this point it also seems that only one of every 
thousand spermatozoa succeeds in reaching the Fallopian tube. Hence, only approxima-
tely 200 spermatozoa of the ejaculate arrive into the proximity of the oocyte.19 
During their lime-related passage through the female genital tract, spermatozoa 
undergo a series of morphological, biochemical and physiological alterations before 
they acquire the capacity to fertilise.20 These processes by which the sperm surface is 
transformed are called capacitation and acrosome reaction. Capacitation is essential for 
penetration of the zona pellucida and acrosome reaction is a necessary event sperm must 
undergo to fuse with the oocyte membrane. Capacitation and acrosome reaction can also 
successfully be completed in appropriately chosen in vitro culture conditions.2123 The 
fertilisable life span of human spermatozoa is uncertain but probably around 48-72 
hours, although motility can be maintained after the sperm has lost the ability to ferti-
lise.24-26 The duration of life of the human oocyte ranges between 12 and 24 hours.27 
Thus, fertilisation is only possible two to three days prior to and on the day of ovulation. 
This is an intrinsic restriction of human fertility, however, the conditions in the female 
for conception are optimal at this time. 
Following ovulation, that is the release of the oocyte from the Graafian follicle of the 
ovary, the oocyte is picked up by the fimbriated end of the fallopian tube. Most likely 
the ampulla is the site of fertilisation in the human. The oocyte is surrounded by the 
zona pellucida, an acellular layer, which becomes impervious to other sperm after 
fertilisation. The first meiotic division is resumed during ovulation and completed in the 
oviduct following sperm penetration. One spermatozoon penetrates the zona pellucida, 
subsequently there is fusion of the vitelline membranes of the oocyte and the 
spermatozoon. Then the chromatin material of the sperm head décondenses and the 
male pronucleus is formed. After the male and female pronuclei have been fused, 
fertilisation is accomplished, and cleavage starts while the ovum is being transported to 
the uterus. The fertilised ovum implants in the uterus around six to seven days after 
fertilisation.28 By then, it has developed to the stage of a blastocyst. 
The human conceptus produces human chorionic gonadotrophin (hCG) which can be 
measured in the maternal plasma at approximately day eight of pregnancy.29·30 The 
function of the corpus luteum is crucial during the first stage of pregnancy and optimal 
hormonal conditions are necessary for implantation. It is difficult to estimate the true 
incidence of fertilisation and implantation. It is assumed that circa 50% of the fertilised 
ova and embryos are lost during the luteal phase without a delay of menstruation and 
this phenomenon is known as early conceptual loss.31 
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1.2.2 Hormonal pattern of the menstrual cycle 
The menstrual cycle upon which fertility depends is characterised by a complex but 
orderly sequence of endocrinological and morphologic events. Complex interrelation-
ships exist between the hypothalamus, the anterior pituitary and the ovaries. The 
menstrual cycle is a consequence of the integration of the signals of these three com-
ponents into a control system with negative and positive endocrine feedback mecha-
nisms as well as neural inputs from higher central nervous system centers, (for reviews 
see e.g. 32-35) 
The hypothalamus produces gonadotrophin releasing hormone (GnRH) which is 
released into the portal circulation in an intermittent or pulsatile way. Follicle Stimu-
lating Hormone (FSH) and Luteinising Hormone (LH) are synthesised and secreted in 
the anterior pituitary in response to GnRH and arc also released in bursts. Oestrogens 
from the ovaries have an important modulating effect on the pituitary and the 
hypothalamus. The physiology of the normal cycle can at best be described by dividing 
the cycle into three major phases: the follicular phase, the ovulatory phase and the luteal 
phase. 
Follicular growth is a continuous autonomous process which lasts from fetal life until 
the menopause, but without adequate gonadotrophic stimulation the follicles become 
atretic in an early stage. 
At the end of a cycle when the corpus luteum regresses and progesterone and 17ß-
oestradiol levels decline, the negative feedback of these steroids on FSH levels is low. 
The rise in FSH levels rescues a group of follicles from atresia. These primordial 
follicles consist of an oocyte surrounded by granulosa cells. FSH stimulates the 
aromatisation of androgens to 17ß-oestradiol in the granulosa cells and 17ß-oestradioI 
levels increase progressively. Both FSH and oestradiol have a stimulatory effect on the 
proliferation of the granulosa cells. Through negative feedback of oestradiol the 
secretion of FSH declines. The rise in the secretion of oestradiol has a negative 
feedback effect on the hypothalamus and pituitary and prevents other follicles to 
develop. The androgen precursors of oestradiol, mainly androstenedione, are produced 
by the cells of the theca interna and the stromal tissue under the stimulatory effect of 
LH. The plasma level of LH slowly increases. An androgenic milieu and a prematurely 
elevated LH level inhibit the granulosa cell proliferation and cause degenerative 
changes in the oocyte. By the sustained accumulation of granulosa cells the primordial 
follicle changes into a preantral follicle and subsequently into an antral follicle which 
contains follicular fluid. Selection of the dominant preovulatory follicle has occurred by 
the middle of the proliferative phase.36 
At high concentrations such as in the late follicular phase, the negative feedback of 
oestradiol changes into a positive feedback resulting in a surge of LH and FSH.37 The 
oestradiol concentration is maximal 24 - 36 hours prior to ovulation and drops after the 
LH surge. The rising levels of LH in the late follicular phase cause luteinisation of the 
granulosa cells with increased production of progesterone prior to the LH peak and 
ovulation. This results in slightly increased serum progesterone levels just prior to the 
3 
onset of the LH surge. There is some evidence that progesterone may be essential for 
inducing the preovulatory surge of FSH and that it facilitates the LH release at mid-
cycle.38 Approximately 28 - 32 hours after the onset of the LH surge and 10 to 12 hours 
after the LH peak the oocyte is released from the follicle, i.e. ovulation, and the follicle 
is transformed into a corpus luteum. 
Normal luteal function requires optimal preovulatory follicular development. During 
the luteal phase progesterone in the serum increases steadily to maximum levels which 
are reached at circa six to eight days after the LH peak. The corpus luteum produces 
also oestradiol, 17a-hydroxy-piOgesterone and androgenic steroids. The oestradiol 
concentration also rises in the luteal phase but the maximum concentration is only one 
third of the preovulatory peak. Through negative feedback of progesterone and oestra-
diol on LH and FSH production the growth of new follicles is inhibited. Unless 
pregnancy occurs regression of the corpus luteum starts circa 10 days after ovulation 
and the steroid levels decline. Subsequently the FSH level increases and a new men-
strual cycle is initiated. 
The physiological role of nonsteroidal factors in the control of the menstrual cycle 
has not fully been established as yeu Whether inhibin, a nonsteroidal regulator in 
follicular fluid, is a normal component of feedback regulation is unknown. It is sup-
posed selectively to suppress the secretion of FSH from the pituitary gland.39 
1.2.3 Androgenic steroids 
In the female androgenic hormones originate from the adrenal cortex, from the stromal 
tissue, theca interna and corpus luteum of the ovaries, and from peripheral conversion 
of other androgenic steroid precursors, (for reviews see 40-42) 
The androgens most extensively studied are testosterone, 5a-dihydrotestostcrone 
(DHT), androstenedione, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone 
sulphate (DHEAS). DHEA and DHEAS are secreted primarily by the adrenal glands: 
80% and 90%, respectively.40 Approximately 50% of testosterone levels arise from 
peripheral conversion of androstenedione, while the adrenal and ovary contribute 
equally to the remaining 50% of the circulating levels of testosterone. Androstenedione 
is secreted directly by both the adrenals and ovaries in around equal amounts.41 
The secretion of androgens is controlled by the hypothalamus and the pituitary. 
Adrenal androgen production is stimulated by the adrenocorticotrophic hormone 
(ACTH) and probably by other factors.43 Prolactin has also been considered to stimu-
late adrenal androgen secretion, by potentiating the effect of ACTH on adrenal 
androgen release.43·44 Prolactin may also play a role in peripheral androgen meta-
bolism.44 However, Walhen et al.46 found an inverse relationship between prolactin and 
both DHEAS and testosterone. The production of ovarian androgens is stimubted by 
the gonadotrophins, mainly LH.47 In the ovary androgens are the precursors of ocstro-
gens. In the granulosa cells androstenedione is aromatised to oestradiol.48 
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The intrinsic biological activity of the androgens is different: testosterone and DHT 
show a very strong androgenic activity, whereas DHEA and DHEAS are less potent 
androgens.49 
Most androgens are bound to proteins in plasma.50 Circa 80% of the circulating 
testosterone is bound to sex hormone binding globulin (SHBG).51 This carrier protein 
has also an affinity for other androgens and oestrogens. Furthermore, the production of 
SHBG is decreased by androgens and increased by oestrogens. Approximately 19% of 
testosterone is bound to albumin, whereas only 1% is unbound and free. Only the 
unbound proportion of a hormone is able to exert biological activity. Most assays of 
serum testosterone measure the total testosterone concentration, i.e. both the amounts of 
protein-bound and -unbound. DHEA, DHEAS and androstenedione are not significantly 
protein-bound. Measurement of androgenic steroids in saliva are reported to correlate 
well with the concentrations of nonprotein-bound hormones in blood.52·53 
Androstenedione, testosterone and DHEA all show diurnal changes similar to that of 
Cortisol.54 Some studies also show androstenedione and testosterone to exhibit cyclical 
patterns. During the periovulatory period the levels of these androgens are elevated due 
to increased ovarian production, but variations in ovarian androgen secretion can be 
masked by fluctuations in adrenal secretion.40·41 
1.3 THE GENERAL FERTILITY WORKUP PROGRAM 
The burden of the investigation and treatment of infertility for the patient should not be 
underestimated. In the first place a fertility workup program should be systematic and 
the most easily performed, non-invasive tests must be carried out first. The basic ferti-
lity survey should be performed as rapidly as possible. Furthermore the infertility 
investigation has to be complete as infertility often can be multifactorial in origin. The 
investigation and management of infertility must be handled with care as it may affect 
the couple's sexual life and social function. Accurate information and emotional support 
by the physician may diminish the psychological strain. 
The main items of a fertility workup program are:10·55 
- Medical history 
- General physical and pelvic examination 
- Basal body temperature (BBT) records with hormonal assays if necessary 
- Semen analysis (SA) 
- Examination of sperm-cervical mucus interaction 
- Tests of tubal function 
The initial assessment of the infertile couple should begin with a thorough and syste-
matic medical history and physical examination of both partners. The first visit also 
gives the opportunity to inform the couple about the examinations and tests that will 
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follow. If no gross abnormalities become apparent the next steps should be BBT charts 
for the wife and semen analyses for the husband. 
The recording of the basal body temperature gives indirect information on the 
occurrence and time of ovulation. The pattern throughout the cycle rather than the 
absolute temperature values is important in the interpretation of the BBT record. 
However, when correlated with endocrinological or ultrasonographical markers the 
BBT is not always reliable.5658 The BBT chart is helpful when it is clearly biphasic. 
When the pattern is doubtful or when the exact day of ovulation must be detected 
additional information is needed. Additional cycle evaluation can be obtained by 
measurement of reproductive hormones enabling the diagnosis of hyperprolactinemia, 
and/or hyperandrogenism. Follicular growth and the occurence of ovulation can be 
detected by ultrasound. 
Semen analysis is the most important test in the evaluation of male fertility and must 
be carried out at least twice at two different occasions with an interval of at least six 
weeks. It is a quantitative test which gives information on number, motility and mor-
phology of the spermatozoa, in addition to several characteristics of seminal fluid 
parameters. A functional test in the evaluation of male fertility can be the zona-free 
hamster ovum sperm penetration assay (SPA).59 This assay determines the capability of 
human spermatozoa to penetrate hamster oocytes from which the cumulus and the zona 
pellucida have been removed. The spermatozoa have to be preincubated to capacitate. 
It is a relatively laborious test to perform, while its indications and clinical signifi-
cance is still subject of discussion.60·61 
The next step is the evaluation of the sperm-mucus interaction. The postcoital test is 
scheduled just prior to ovulation. Within 8 the 12 hours after intercourse, some mucus is 
obtained from the cervical canal and viewed under the microscope (magnification 
400x). The quality of the mucus is determined and expressed in terms of amount, 
"Spinnbarkeit", feming and clarity.62·63 The quality of the cervical mucus is an indirect 
indicator of relative levels of oestradiol and progesterone: oestradiol stimulates its 
quantity and properties whereas progesterone has an opposite effect17 If the poor 
mucus quality is related to inaccurate timing, the postcoital test should be repeated. The 
test is judged positive if at least five spermatozoa with good forward progression per 
field can be seen at 400x magnification. If the postcoital test is negative despite good 
scheduling, another test -the sperm penetration meter (SPM) test- gives the opportunity 
to observe the sperm-mucus interaction in vitro. In vitro testing by applying donor 
mucus or donor sperm can be an aid to determine whether the poor postcoital test is 
either due to factors in the mucus or to intrinsic defects in the sperm.64·65 
Sperm antibody testing should be performed in all cases of agglutination of the 
spermatozoa.66 
Usually the last and most invasive step in a basic fertility survey is testing of tubal 
patency. A hysterosalpingogram images the inner contours of the uterine cavity and the 
patency of the Fallopian tubes. The way in which the contrast medium spreads into the 
peritoneal cavity may provide information on tubo-peritoneal pathology. By laparo-
scopy the inner pelvic organs can be visualised and inspected. Adhaesions and endome-
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tnosis can be detected and tubal patency can be tested by chromepertubation of the 
Fallopian tubes. 
The investigation of an infertile couple should be systematic, rational and directed 
towards the individual problems. 
1.4 OUTLINE OF THE PRESENT INVESTIGATION 
The purpose of the present study was to investigate the processes of oocyte maturation, 
ovulation and corpus luteum function in the female and to determine how these proces-
ses could be assessed in an optimal and rational manner in a fertility workup program. 
Since there is evidence that a number of pregnancies are lost previous to the menstrual 
period, the phenomenon of early conceptual loss in the luteal phase was studied in 
addition to the corpus luteum function as a possible cause of unexplained infertility. 
Furthermore the value of newly developed diagnostic methods to determine male 
fertility was assessed. 
To elucidate these problems the investigation was divided in three parts: 
I: A prospective, extensive study of the menstrual cycle in infertile and assumed 
fertile women took place. Their ovarian function was assessed by frequent sampling of 
blood and saliva in which the full range of relevant hormone determinations were per-
formed. Three study groups were investigated: a group of women with irregular cycles 
and women of couples suffering from unexplained infertility with apparently normal 
cycles were both compared with a control group of normally cyclic women. 
II: The problem of early conceptual loss was studied prospectively. Frequent 
determinations of hCG took place during the luteal phase of two groups of women. 
Twenty infertile women of couples with unexplained infertility formed the study group 
and 20 normally fertile women who were trying to conceive formed the control group. 
Ill: The value of the SPA, a functional test of the fertilising capacity of human 
spermatozoa was evaluated by comparing this test with the routine semen analysis, the 
SPM test and IVF with special attention to the post-capacitation motility. 
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CHAPTER 2 
SUBJECTS, MATERIALS AND METHODS 
2.1 INTRODUCTION 
Three groups of patients were selected to participate in an extensive fertility workup 
program. Twenty women with proven or assumed normal fertility formed the control 
group. Thirty-five infertile women who attended a gynaecologist for their infertility par­
ticipated also in the investigation. These patients were divided into two study groups: 
fifteen patients with irregular menstrual cycles and twenty patients with apparently 
normal menstrual cycles, but suffering from unexplained infertility. 
An extensive study of endocrine parameters of the menstrual cycles of these three 
groups took place. Blood and saliva samples were collected at regular intervals through­
out one cycle. Twelve endocrine parameters were determined in the serum samples and 
eight hormone determinations took place in the saliva samples. 
The results of the group with irregular cycles vs. the control group and of the group 
with unexplained infertility vs. the control group were evaluated. 
2.2 SELECTION OF SUBJECTS 
2.2.1 Selection criteria for the control group 
Twenty healthy women were willing to participate in the investigation as a volunteer. 
They were attending a gynaecologist for a problem not interfering with the investigation 
of their menstrual cycle, e.g. candidates for laparoscopic tubal obstruction or an intra­
uterine device. Some women of the control group were hospital workers or students and 
the remaining women were recruited by means of an advertisement in a local paper. 
The following criteria were used for admittance into the control group: 
- A history of regular menstrual cycles, as a rule ranging in length from 26 - 32 days, 
during the last three months; 
- Younger than 38 years; 
- No hormonal or other medication; 
- No pregnancy от lactation period during six months preceding the investigation; 
- No obesity, as indicated by the Quetelet-index (see 2.3); 
- Good general health. 
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2.2.2 Selection criteria for the infertile women with irregular cycles 
The group of women with abnormal menstrual cycles comprised fifteen women with a 
complaint of infertility of at least one year. They had repeatedly irregular cycles: i.e. 
menstrual intervals of less than 26 days or between 32 and 90 days, whether ovulatory 
or anovulatory as judged by previous Basal Body Temperature (BBT) charts. 
2.2.3 Selection criteria for the women with unexplained infertility 
The following conditions had to be fulfilled for the women suffering from unexplained 
infertility: 
- Duration of infertility for at least one year, 
- Regular, ovulatory menstrual cycles, confirmed by BBT charts, with menstrual 
intervals as a rule between 26 and 32 days; 
- Normal semen analysis of the partner on at least two occasions. (Sperm count >20 χ 
IO6 /mL, £50% of the spermatozoa with good forward progression and >60% mor­
phologically normal spermatozoa). Despite normal semen analyses before admittance 
in the investigation, some men showed one or more abnormal semen parameters 
during the study; 
- Positive postcoital test, i.e. at least five spermatozoa with good forward progression 
per field, magnification 400 x; 
- Tubal patency, no adhaesions and no endometriosis. 
2.3 CLINICAL CHARACTERISTICS OF THE SUBJECTS 
Table II. 1 presents details concerning age, height and weight of the subjects. The 
Quetelet index1 was used to determine the relative body weight. This index can be 
calculated from the formula: 
body weight / k g \ 
( χ 105 ) 
height2 v cm2 ' 
The age, height and weight distributions of the women of the three groups were 
comparable. All women had a Quetelet-index in the expected normal range for their 
age.2 
The control group comprised nine women who had never been pregnant and eleven 
women with one or more children and/or one or more abortions. In the control group the 
length of the study cycle ranged from 24 to 36 days, despite previous cycle lengths of 
26 to 32 days. Two women had short cycles of 24 and 25 days, respectively, and three 
women had cycle lengths of 33, 35 and 36 days, respectively, during the investigation. 
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Table ILI Age, height, weight and Quetelet-index of the investigated groups 
Age (years) 
control group 
irregular cycles 
unexpl. infert 
Height (cm) 
control group 
irregular cycles 
unexpl. infert. 
Weight (kg) 
control group 
irregular cycles 
unexpl. infert. 
Quetelet-index ( 
control group 
irregular cycles 
unexpl. infert. 
η 
20 
15 
20 
20 
15 
20 
20 
15 
20 
kg 
χ 105) 
cm
2 
20 
15 
20 
Mean 
27.8 
28.6 
27.9 
167.8 
166.9 
166.9 
59.7 
58.7 
59.5 
211.7 
210.5 
213.8 
SD 
4.8 
3.1 
3.7 
8.1 
5.9 
5.7 
7.4 
6.0 
7.7 
18.9 
17.8 
27.4 
Range 
Min. Max. 
19 
22 
20 
151 
156 
158 
50 
49 
44 
186.1 
177.8 
161.6 
37 
33 
34 
180 
176 
178 
79 
71 
79 
258.0 
235.9 
267.0 
Median 
29 
28 
28 
169 
168 
167 
58 
57 
59 
206.4 
212.6 
208.0 
Due to cycle variation this could be expected. Additionally, other investigators consider 
cycle lengths of 24 or more days, but not longer than 36 days as normal.3 
The median length of the study cycle of the women with irregular cycles was 35 days 
(range 2 6 - 4 9 days). In the group with unexplained infertility the median duration of 
the investigated cycle was 27 days. Three women had a cycle length of 24 days during 
the investigation and in two women the study cycle lasted 39 and 63 days, respectively. 
Table II.2 gives information on the length of the follicular phase, defined as the 
interval in days between the first day of menstruation up to and including the day of the 
LH peak and on the length of the luteal phase, defined as the interval following but not 
including the day of the LH peak until the day preceding next menstruation. When 
presenting the hormonal data in chapter 3 and 4 also a peri-ovulatory phase is 
introduced including the day of (he LH peak, the previous 2 days and the day after the 
LH peak. 
Of the fifteen women with irregular cycles ten suffered from primary infertility and 
five were secondary infertile. In the group of unexplained infertility two women had 
been pregnant at least once, the remaining 18 women never had achieved a pregnancy. 
The distribution of the duration of the infertility was not significantly different for the 
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Table II.2 Cycle lengths and lengths of the follicular and luteal phases of the inves­
tigated menstrual cycles of the three study groups 
Cycle 
Length 
(days) 
Follicular 
Phase 
(days) 
Luteal 
Phase 
(days) 
Control 
Irregular 
Unexplained 
Control 
Irregular 
Unexplained 
Control 
Irregular 
Unexplained 
Median 
29 
35 
27 
17 
19 
13 
13 
14 
14 
Range 
24-36 
2649 
24-63 
12-23 
14-35 
1049 
10-16 
10-17 
11-17 
Mean 
29.0 
34.4 
29.6 
15.8 
19.6 
15.8 
13.2 
14.5 
13.8 
two infertile groups (median 30 vs 35 months). The longest duration of infertility was 
six years in both groups. 
In both infertile groups seven women visited the outpatient department for a second 
opinion of their infertility problem after having been investigated and/or treated else­
where. 
All women were examined for their general health. Anaemia was excluded by 
measuring haemoglobin levels. Liver, renal and thyroid function parameters were 
determined to assure normal function of the most important organs which can interfere 
with the function of the hypothalamic-pituitary-ovarian axis. The median values and 
ranges of some non-hormonal data and thyroid function are presented in table II.3. 
Table Π.3 Concentrations of non-hormonal and thyroxine determinations in serum. 
Median (range) 
Control 
8.4 (7.7-9.4) 
45 (2.1-5.9) 
62 (54-78) 
0.17 (0.09-026) 
12 (6-23) 
10 (8-24) 
172 (141-268) 
95 (75-130) 
Irregular cycles 
8.2 (7.5-9.4) 
4.4 (1.4-5.6) 
65 (53-77) 
0.20 (0.12-0.27) 
12 (8-16) 
10 (4-18) 
178 (133-216) 
110 (88-130) 
Unexplained 
Infertility 
8.4 (7.2-9.2) 
3.7 (2.3-6.1) 
64 (53-73) 
0.19 (0.12-0.29) 
12 (4-17) 
8 (5-16) 
185 (134-222) 
110 (97-150) 
Reference 
Values 
8.0-9.5 
2.5-5.8 
53-80 
0.12-0.32 
10-30 
10-30 
150-250 
58-148 
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Hb (mmol/L) 
Urea (mmol/L) 
Creatinine (jimol/L) 
Uric acid (mmol/L) 
ASAT (U/L) 
ALAT (U/L) 
LD (U/L) 
T4 (nmol/L) 
2.4 SEMEN CHARACTERISTICS 
In all partners of the women with irregular menstrual cycles and the women of the 
group with unexplained infertility a semen analysis (SA) was carried out additionally to 
the SAs that were performed during the fertility evaluation before admission to this 
study. A SA was performed in nine partners of the control group of assumed fertile 
women. Seven men of the last group had proven their fertility. The results of the SAs of 
each group are shown in table II.4. 
Table Π.4 Semen parameters of the investigated groups Median (range) 
Semen 
Parameter 
Volume (mL) 
Density (xlOfymL) 
Motility (%) 
Motility grade 
Abnormal forms (%) 
Control 
Group 
n=9 
5.2 (1.1-8.2) 
61 (20-330) 
60 (30-100) 
4-5 (4-6) 
35 (24-58) 
Irregular 
Cycles 
n=15 
2.7 (1.1-10.0) 
45 (6-100) 
50 (10-100) 
4-5 (2-6) 
41 (27-65) 
Unexplained 
Infertility 
n=20 
3.9 (1.6-6.5) 
50 (8-190) 
55 (5-100) 
4-5 (3-5) 
36 (25-51) 
The criteria of this laboratory for a normal SA are: sperm density >20 χ lOfymL, 
percentage motility >50%, motility grade >4 and <40% abnormal forms. 
In the control group five out of nine men had a normal SA. Three men had one 
abnormal semen parameter and one male had two abnormal semen characteristics. The 
latter male had proven his fertility. 
Five partners of women with irregular menstrual cycles had a normal spermiogram. 
The remaining ten men of this group had one or two abnormal sperm characteristics. 
Despite the selection criterion of two normal SAs, only ten out of twenty males of the 
group with unexplained infertility had a completely normal SA. Six men had one 
slightly abnormal semen parameter and four males had a combination of two or three 
abnormal characteristics. 
Furthermore the zona-free hamster ovum sperm penetration assay (SPA) was carried 
out in eight men of the control group, in fourteen partners of women with irregular 
cycles and in all men of the group with unexplained infertility. Prior to the incubation of 
the washed spermatozoa with the hamster oocytes the motility grade was determined.4 
The results of the SPA with regard to the motility after preincubation are shown in table 
U.S. None of the men with insufficient motility after preincubation had a positive SPA. 
In case of good motility after preincubation the majority of males in all three groups had 
a positive SPA. Despite proven fertility only four out of eight men showed a positive 
result in the SPA. The remaining three men had an insufficient motility after 
preincubation and one man had penetration rate of 0% in the SPA, although the motility 
after preincubation was sufficient. It was demonstrated in all three groups that in almost 
all semen samples which showed insufficient motility after preincubation and/or a nega-
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live SPA also one or more abnormal semen parameters were determined in the routine 
SA of the same semen sample. The majority of men with a normal spermiogram also 
had a positive SPA. 
Table Π.5 Number of men of the investigated groups with a positive SPA (penetration 
rate >0%), out of subgroups with either sufficient, insufficient or without motility after 
preincubation 
Control Irregular Unexplained 
Group Cycles Infertility 
n=8 n=14 n=20 
Motility grade after preincubation >4 4/5 7/9 14/15 
Motility grade after preincubation <4 0/1 0/3 0/3 
Immotile after preincubation, SPA cancelled 2 2 2 
2.5 SCHEDULE OF OBSERVATIONS 
The aim of this study was to observe the hormonal pattern in normal and 'infertile' 
menstrual cycles. Frequent venous blood samples were taken during one menstrual 
cycle without medication. Blood samples were collected every other day during the fol­
licular and luteal phase, and during the periovulatory phase blood samples were 
obtained daily. Saliva was obtained on two occasions during each phase of the cycle. 
Whole saliva was collected at home by the women and immediately frozen after 
collection. Blood and saliva were collected between 8 and 12 a.m., but not always at the 
same time. 
To determine the phase of the cycle follicular growth and ovulation were observed by 
ultrasound (Real-time В scan, Toshiba Sonolayer-L SAL 20A, 2.4 MHz transducer). 
Depending on the duration of the previous cycles, the first ultrasound examination took 
place at around five days before the expected day of ovulation and examinations were 
continued until ultrasonographical signs of follicle rupture had occurred. Furthermore 
all women recorded a BBT chart. 
Prophylactic ferrosulphate medication (Fero-Gradumet®, Abbott Nederland B.V.) 
was offered to all women during the study cycle. 
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2.6 IMMUNOCHEMICAL PROCEDURES IN SERUM AND 
SALIVA 
2.6.1 Preparation of serum and saliva 
Serum was obtained by vena puncture and after clotting and centrifugation, serum was 
frozen at -20° С until assays were performed. Saliva was collected at home and frozen 
until assayed. 
The concentrations of thirteen different hormones and binding proteins involved in 
fertility regulation have been determined in the serum samples and eight of these were 
also quantified in the majority of the saliva samples collected. 
In serum this scries concerned: Luteinising hormone (LH), Follicle stimulating 
hormone (FSH), prolactin (PRL), and thyroxine (T4), as well as the steroid hormones 
17ß-oestradiol (Оег), progesterone (Prog), 17a-OH-progesterone (170HP), androstene-
dione (Andr), testosterone (Test), Dehydroepiandrosterone (DHEA), dchydroepian-
drosterone-sulphatc (DHEAS) and Cortisol, and sex-hormone binding globulin (SHBG). 
All the above mentioned steroid hormones have also been determined in the saliva. 
Some components allowed the direct determination in serum (LH, FSH, PRL, Cortisol, 
DHEAS and SHBG) or saliva (DHEAS and Cortisol), whereas the remaining com­
ponents required a sample purification procedure prior to estimation. In the case of 
serum the quantitation of Οβ2, Prog, Test and DHEA was preceded by extraction of the 
samples with diethylether, whereas in the case of 170HP and Andr the extraction was 
followed by chromatographic isolation of the steroids by applying Sephadex LH-20 
prior to assay. 
The determination of all steroid hormones in saliva (except DHEAS and Cortisol) 
was performed after both diethylether extraction and Sephadex LH-20 separation. 
All the applied organic solvents were of analytical grade and purchased from E. 
Merck, Darmstadt, F.R.G. 
2.6.1.1 Extraction with diethylether 
In order to allow the correction for procedural losses due to the sample purification 
procedures previous to immunochemical assay amounts of 1000 cpm of the appropriate 
tritiated steroid were added to 0.5 mL of serum or 4.0 mL of saliva samples and this was 
followed by incubation for 10 min at room temperature. Next, the serum and saliva 
samples were extracted twice with 4 mL and 16 mL diethylether, respectively, and the 
combined ether layers were dried under a stream of nitrogen. If the measurement of a 
given component only required extraction, the residues of the organic layers were 
dissolved in 0.5 mL assay buffer and then assayed, else residues of the the extracts were 
dissolved in 0.2 mL Iso-octane: Toluene: Methanol (I:T:M) = 90:5:5 (v/v) in order to 
prepare for the chromatographic separation procedure on micro columns filled with 
Sephadex LH-20. The percentages of recovered tritiated steroids after extraction were 
always >85%. 
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2.6.1.2 Chromatography on Sephadex LH-20 
The chromatographic separation of the steroids from the diethyl-ethcr extracts into 
distinct effluents was performed on micro columns fdled with 0.5 g Sephadex LH-20 
(Pharmacia AB, Uppsala, Sweden). The columns were developed with the solvent 
mixture I:T:M = 90:5:5 and the locations of the different steroids in terms of effluent 
portions were: Prog 1.5-4.0 mL; Andr 3.5-7.0 mL; DHEA 6.0-9.0 mL; Test 8.5-12.5 
mL; and 170HP 10.5-14.0 mL. After this procedure Осг was isolated at 2.0-6.0 mL of 
effluent by applying I:T:M = 60:20:20. 
As can be derived from the locations of the respective steroids it is not possible to 
separate all the steroids in one distinct chromatography run. Thus, two different runs 
were performed to achieve the complete separation of all the steroids. The combinations 
Prog-DHEA-170HP and Andr-Test-Oe2 were selected and in practice, 3H-steroids 
added to serum or saliva (prior to extraction and subsequent chromatography) were 
recovered with percentages ranging between 65-85%. 
Once the Sephadex LH-20 separation had been performed the effluents were dried 
under a stream of nitrogen and the residues were taken up in 0.5 mL of assay buffer. 
Figure 2.1 depicts the chromatograms of the two runs for the isolation of these steroids. 
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Figure 2.1 Sephadex LH20 chromatograms for the isolation of steroids from saliva 
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2.6.2 Assay methods 
Quantitation of the analytes contained in the serum or saliva samples (irrespective of 
whether direct assays or purification procedures prior to assay were involved) was 
performed with two types of immunoassays; competitive radioimmunoassays (RIA) on 
the one hand, or immunoradiometric "sandwich-type" assays (IRMA) on the other. In 
the case of each individual assay a series of known amounts of the respective standard 
was assayed to compose a stan-dard dose-response curve. From such curves the 
individual responses of the unknowns were read to calculate the concentrations of the 
analyte contained in these samples. In the case of RIA the response variable (i.e. the 
amount of radioactivity of a labelled standard preparation bound to the antibody) 
decreases with increasing amounts of standard whereas in the case of IRMA increas-ing 
amounts of radioactivity are observed with increasing amounts of standard. 
2.6.2.1 Radioactivity measurements and calculation procedures 
All the performed assays made use of radioactive labelled hormones or antibodies. For 
this purpose the majority of steroids involved (except for Cortisol) applied tritium (ЗН, a 
weak beta-emitting radionuclide) which substitutes up to six hydrogen atoms of the 
original steroid molecule. These commercially available steroid preparations (Amers-
ham International pic, Amersham, England) were quantified by means of liquid scintil­
lation counting for which we used a "1209 Rackbeta Primo" liquid scintillation counter 
(Pharmacia-Wallac Oy, Turku, Finland). 
The other assays were based on the application of 1 2 5 I which is a gamma-emitting 
isotope. This radionuclide was coupled either tostandard material of the analyte to be 
measured or to one of the antibodies used. The quantitation of 1 2 5 I was detected directly 
in a "1261 Multigamma Counter" (Pharmacia-Wallac Oy, Turku, Finland). 
Concentrations of the various analytes were calculated from the counting data using a 
sophisticated software package (RiaCalc LM Programme) commercially available from 
Pharmacia-Wallac Oy, Turku, Finland. In the case of scintillation counting the counting 
data were stored on a floppy diskette using a "Mariachi Seed 2" diskdrive (Mariachi Oy, 
Turku, Finland) and the calculations were performed afterwards. If on the other hand 
1 2 5 I was involved the calculations were performed on-line with the RiaCalc package 
loaded into a PC while using the gamma counter. 
Within the Riacalc programme RIA results were calculated follow-ing logit-log 
transformation of the dose-response data5, whereas IRMAs were always based on 
calculations using "spline" functions.6 
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2.6.2.2 Assay validation: reliability criteria 
The reliability of all the applied RIA and IRMA assays was investigated according to 
the following criteria: 
- The analytical sensitivity of an assay in terms of the minimal detectable dose of 
analyte was defined in the case of RIA as the dose reading at zero-dose binding 
minus twice the standard error (SE). In the case of IRMA the dose reading at zero-
binding plus twice the SE was used. Results of analytical sensitivities with each 
assay are given in Table 11.6a. 
- The precision of an assay was calculated from the means of duplicate measurements 
of several different serum and saliva pools, each after N consecutive assay runs.5 In 
the case of the steroids, two different sample aliquots taken from one pool were 
assayed to cover the response range. Tables П.бЬ and 11.6c depict the percent 
coefficients of variation (CV) of both within (CVW) and between (С ь) assay 
variabilities. 
- The analytical specificity of the applied assays in terms of percent cross-reaction of 
potentially interfering peptide or steroid hormones has been tested according to the 
procedure described by Abraham.7 Thus, the percent ratio of analyte standard over 
the amounts of potentially cross reacting components were calculated at response 
levels of B/BQ = 0.5 and are given in the descriptions of the individual assays. 
- The accuracy of the applied assays can be tested in two different manners: a) 
parallelism between linearised dose-response lines of standards and serially diluted 
unknowns ("parallel line assays", see Tables II.7a and II.7b) by calculating the 
percent recoveries of known amounts of analyte added to serum samples previous to 
extraction and chromatography covering the entire dose-response range. The results 
of these experiments are depicted in Table П.7Ь. 
Table П.ба Sensitivity of thirteen assays 
Assay 
Оег 
Prog 
170HP 
Andr 
Test 
DHEA 
DHEAS 
Sensitivity 
5.0 
25 
10 
5.0 
5.0 
7.5 
7.5 
fmol/mbe 
fmol/tube 
fmol/tube 
fmol/tube 
fmol/tube 
ftnol/tube 
fmol/tube 
Assay 
LH 
FSH 
PRL 
Cortisol 
SHBG 
T4 
Sensitivity 
1.5 
0.35 
30 
10 
1.0 
6.4 
IU/L 
IU/L 
mlU/L 
nmol/L 
nmol/L 
nmol/L 
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Table n.6b Precision of thirteen assays in serum 
Assay 
LH 
FSH 
PRL 
Oe2 
Prog 
170HP 
Andr 
Test 
DHEA 
DHEAS 
Cortisol 
SHBG 
T4 
Dimension 
IU/L 
IU/L 
IU/L 
IU/L 
mlU/L 
mlU/L 
pmol/L 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
цтоІД. 
цтоІД. 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
Pool 
Mean 
16 
64 
5.1 
17 
430 
1200 
820 
39 
6.4 
4.8 
2.6 
17 
7.9 
0.38 
9.6 
55 
110 
26 
99 
184 
Table IL6c Precision of eight steroid assays 
Assay 
Оез 
Prog 
170HP 
Andr 
Test 
DHEA 
DHEAS 
Cortisol 
2.6.3 
Dimension 
pmol/L 
pmol/L 
pmol/L 
pmol/L 
pmol/L 
pmol/L 
nmol/L 
nmol/L 
Applied Assays 
Pool 
Mean 
67 
240 
120 
310 
60 
310 
6.6 
15 
No of 
Runs 
99 
97 
65 
62 
88 
88 
78 
36 
20 
40 
123 
26 
21 
92 
20 
20 
20 
38 
42 
43 
in saliva 
No of 
Runs 
11 
10 
9 
9 
11 
11 
10 
15 
Precision (%) 
CVw 
11 
8.3 
13 
8.1 
5.8 
4.9 
4.3 
4.1 
4.5 
5.5 
4.9 
4.7 
3.8 
3.2 
3.7 
2.1 
2.8 
7.5 
4.7 
3.6 
Precision 
CVw 
4.0 
10 
6.8 
6.7 
8.5 
5.9 
4.2 
6.1 
CVb 
18 
13 
16 
12 
10 
8.5 
7.9 
9.1 
7.7 
10 
6.6 
7.5 
7.3 
6.3 
7.7 
5.6 
4.8 
12 
7.3 
6.7 
(%) 
CVb 
6.6 
11 
11 
12 
11 
8.4 
5.2 
12 
2.6.3.1 Luteinising Hormone 
Serum concentrations of LH were measured by a specific homologous double antibody 
solid-phase RIA as described previously by Van Geelen et al.8 The standard-doses in 
terms of 1s t IRP 68/40 ranged from 4.0-250 IU/L. HCG cross-reacted for 100% whereas 
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the cross-reactivity of all other peptide hormones tested was negligible. Data on 
sensitivity and precision aie given in Tables 11.6a and II.6b. The data on accuracy are 
given in Table II.7a. 
2.6.3.2 Follicle Stimulating Hormone 
Serum concentrations of FSH were measured by a specific homologous double antibody 
solid-phase RIA described by Van Geelen et al.8 Standard-doses in terms of 1st IRP 
78/549 ranged from 1.6-100 IU/L and no cross-reactivity was observed with all peptide 
hormones tested. Sensitivity and precision figures are depicted in Tables 11.6a and II.6b. 
The data on accuracy are given in Table H.7a. 
2.6.3.3 Prolactin 
Serum concentrations of PRL were measured by a competitive solid-phase RIA 
commercially available from Farmos Diagnostica (Turku, Finland). Standard-doses in 
terms of 1st IRP 75/504 ranged from 50-5000 mlU/L and cross-reactivity was <0.01% 
for all peptide hormones tested including hGH and hPL. Assay sensitivity and precision 
data are shown in Tables 11.6a and II.6b. The data on accuracy are given in Tables П.7а 
and II.7b. 
2.6.3.4 17ß Oestradiol 
The levels of OE2 in serum (pmol/L) and saliva (pmoI/L) were measured with the 
specific charcoal RIA as described by Thomas et al.9 This assay was preceded by the 
sample purification procedure as indicated above and made use of an antiserum raised 
in rabbits against OE2-6-(0-carboxymethyl)oxime:BSA. Standard-doses in terms of 
OE2 ranged from 10-1500 fmol/tube. The OE2 assay cross-reacted only with OEj for 
1.0%, whereas all other steroids tested showed cross-reactions of <1%. Sensitivity and 
precision data for serum and saliva are given in Tables 11.6a, II.6b and 11.6c. Data on 
accuracy are depicted in Tables II.7a and II.7b. 
2.6.3.5 Progesterone 
Serum and salivary Prog measurements were performed by a specific charcoal RIA 
according to Thomas et al.9 using an antibody raised in rabbits against lla-hydroxy-
Prog-hemisuccinate: BSA. Standard-doses ranged from 50-3200 fmol Prog/tube. 
Results in saliva are expressed in pmol/L and those in serum samples in nmol/L. The 
applied extraction and chromatographic purification procedures previous to assay have 
been described above. Except for 11-deoxy-corticosteron which has a cross-reaction of 
3.8%, all steroids tested cross-reacted for <1%. Data on sensitivity and precision for 
both serum and saliva are shown in Tables 11.6a, II.6b and 11.6c, while the accuracy of 
the assay is given in Tables II.7a and 11.7b. 
2.6.3.6 17a-hydroxyprogesterone 
The levels of 170HP in both serum (nmol/L) and saliva (pmol/L) were determined with 
a highly specific charcoal RIA as described by Dony et al.10 The assay was preceded by 
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the sample purification procedure already described above. The applied antiserum was 
purchased from Radioassay Systems Laboratories Inc. (Carson, CA, USA) and had been 
raised in rabbits against 170HP-7-carboxyethylthioether:BSA. 
Standard-doses in terms of 170HP ranged from 25-3000 fmol/tube. Progesterone and 
17a-hydroxypregnenolone showed 0.4% and 1.1% cross-reactivity whereas all other 
relevant steroids cross-reacted <0.01%. Sensitivity and precision data are given in 
Tables 11.6a, II.6b and 11.6c. The data on accuracy are given in Tables II.7a and II.7b. 
2.6.3.7 Androstenedione 
The concentrations of Androstenedione in serum (nmol/L) and saliva (pmol/L) were 
measured by a charcoal RIA following the extraclion and chromatography procedures 
described above. The RIA applied a commercially available antiserum (Radioassay 
Systems Laboratories Inc., Carson, CA, USA) which had been raised in rabbits against 
Andr-19-carboxymethylcther:BSA. Standard-doses ranged from 10-1600 fmol Andros-
tenedione/tube. Relevant cross-reactions were observed with DHEA (4.9%), DHEAS 
(6.9%), and 5a-androstanedione (16.8%) whereas cross-reactivity of all other steroids 
tested was <0.5%. Assay sensitivity and precision for both serum and saliva measure-
ments are shown in Tables 11.6a to 11.6c. The data on accuracy are given in Tables II.7a 
and n.7b. 
2.6.3.8 Testosterone 
Serum (nmol/L) and salivary (pmol/L) Testosterone concentrations were measured 
following sample purification (see above) by specific charcoal RIA as described by 
Dony et al.10 The assay uses an antibody raised in rabbits against Tes-3-(0-carboxy-
methyl)oxime: BSA. Testosterone standards ranged from 10-1500 fmol/tube and the 
cross-reactivities for all steroids tested were <0.05% except for 5a-and 5ß dihydro-
testosterone which showed cross-reactions of 48% and 14%, respectively. Sensitivity 
and precision data are shown in Tables 11.6a to 11.6c. The data on accuracy are given in 
Tables II.7a and II.7b. 
2.6.3.9 Dehydroepiandrosterone 
The concentrations of DHEA in serum (nmol/L) and in saliva (pmol/L) were measured 
following sample purification (see above) with a highly specific charcoal RIA as 
described by Reijnders.11 The RIA used an antibody purchased from Radioassay 
Systems Laboratories (Carson, Ca, USA). It has been raised in rabbits against 15ß-
carboxyethylmercapto-DHEA:BSA. Standard-doses ranged from 15-1800 fmol DHEA/ 
tube whereas the cross-reactivity of all the relevant steroids tested was <0.3%. Data on 
sensitivity and precision for both serum and saliva are shown in Tables П.ба, П.бЬ and 
11.6c. The data on accuracy are given in Tables П.7а and II.7b. 
2.6.3.10 Dehydroepiandrosterone-sulphate 
The concentrations of DHEAS in serum (jimol/L) and saliva (nmol/L) without were 
measured without any pre-treatment while using a specific charcoal-based RIA 
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The concentrations of DHEAS in serum (nmol/L) and saliva (nmol/L) without were 
measured without any pre-treatment while using a specific charcoal-based RIA 
described by Reijnders.11 This assay used an antibody raised in sheep against DHEA-
3ß-monohemi-succinate:HSA (Radioassay Systems Laboratories, Carson, CA, USA). 
The DHEAS standards ranged from 15-2000 fmol/tube. Cross-reactions for all steroids 
tested were <0.27% with the exception of DHEA which showed a cross-reaction of 
73%. The high percentage of cross-reactivity of DHEA did not affect the DHEAS levels 
since the concentration-ratio of DHEA/DHEAS in serum is <0.001 and with saliva 
<0.01. Data on assay sensitivity and precision are depicted in Tables 11.6a to 11.6c. The 
data on accuracy are given in Tables II.7a and П.7Ь. 
2.6.3.11 Cortisol 
Measurements of serum (nmol/L) and salivary (nmol/L) Cortisol levels were performed 
with a commercially available competitive coated tube RIA (Baxter Travenol Clinical 
Assays Inc., Boston, Mass, USA) as described previously by Dony et al.10 Standard-
doses ranged from 30-1700 nmol Cor/L. Cross-reactivity was measured for predniso­
lone (73%) and 6-methyl-prednisolone (18%) whereas the cross-reaction of other 
relevant steroid hormones tested was almost negligible. 
Since salivary Cortisol levels were relatively low a small modification to the kit 
procedure was introduced by changing the sample volume from 0.01 mL to 0.10 mL 
without any effect on the assay results. Assay sensitivity and precision data of serum 
and saliva measurements arc given in Tables 11.6a to 11.6c and accuracy is documented 
in Tables П.7а and 11.7b. 
2.6.3.12 Sex Hormone Binding Globulin 
Serum concentrations of SHBG were measured by a commercially available (Farmos 
Diagnostica, Turku, Finland) non-competitive liquid-phase IRMA according to the 
method of Hammond et al.12 Standards were used in the range 6.25-200 nmol SHBG/L 
while no human serum proteins are known to cross-react with this assay. Data on 
precision and sensitivity are shown in Table 11.6a and II.6b. The data on accuracy are 
given in Table 11.7b. 
2.6.3.13 Thyroxin 
Measurements of serum T4 levels were performed with a commercially available com­
petitive coated RIA (Baxter Travenol Clinical Assays Inc., Boston, Mass., U.S.A.) as 
applied previously by Reijnders.11 Standard-doses ranged from 13-260 nmol T4/L. 
Cross-reactivity was determined for L-T3 (2.6%) and D-T3 (2.1%) and cross-reactions. 
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Table П.7а Accuracy: Parallel line assay in serum 
Assay Dimension B/B0- N Dose 
LH 
FSH 
PRL 
Oe2 
Prog 
170HP 
Andr 
Test 
DHEA 
DHEAS 
Cortisol 
IU/L 
IU/L 
mlU/L 
pmol/L 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
nmol/L 
(imol/L 
pmol/L 
Range(%) 
89-20 
79-11 
88-28 
89-32 
83-16 
85-20 
87-25 
80-16 
81-10 
79-17 
81-25 
12 
17 
10 
10 
8 
9 
10 
10 
12 
8 
9 
Mean ± SE 
91.1 ± 
76.6 ± 
2330 ± 
1270 ± 
24.8 ± 
15.9 ± 
6.1 ± 
13.4 ± 
33.5 ± 
9.1 ± 
0.40 ± 
7.9 
8.6 
360 
117 
2.6 
1.5 
0.14 
1.1 
3.8 
0.70 
0.03 
(%CV) 
(8.6) 
(11.2) 
(15.2) 
(9.2) 
(10.3) 
(9.3) 
(6.8) 
(8.2) 
(11.3) 
(7.8) 
(6.4) 
Table 11.7b Accuracy: Recovery of standard analyte added to serum 
Recovery (%) 
Assay 
PRL 
Oe2 
Prog 
170HP 
Andr 
Test 
DHEA 
DHEAS 
Cortisol 
SHBG 
T4 
N 
10 
30 
16 
24 
28 
18 
16 
20 
20 
10 
20 
Meant SE 
103 
100 
97 
96 
97 
99 
101 
97 
102 
91 
100 
± 22 
± 10 
± 15 
± 11 
± 13 
± 7.8 
± 12 
± 5.9 
± 4.0 
± 5.5 
± 6.3 
(%CV) 
(21) 
(10) 
(15) 
(11) 
(13) 
(7.9) 
(11) 
(6.1) 
(3.9) 
(6.0) 
(6.3) 
2.7 DATA HANDLING AND STATISTICAL ANALYSIS 
2.7.1 Data handling 
The intention of the study was to obtain blood samples every two days during the 
follicular and luteal phase and daily during the peri-ovulatory phase. Furthermore saliva 
was designed to be collected on two occasions during each phase of the cycle. Retro­
spectively in some women blood and/or saliva samples were incomplete during one or 
more phases of their cycle. 
The day of the highest LH concentration is designated day 0. The day of the LH peak 
was obvious in 44 out of the 55 women. The remaining eleven women showed no clear 
LH peak because of incomplete daily serum sampling during the periovulatory period. 
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To determine the expected day of the LH peak the available hormonal data of these 
women were submitted to five independent observers who are specialised in infertility 
problems. The day which was designated day 0 by a majority of the observers was 
assumed to be the day of the LH peak. 
The days preceding the mid-cycle LH peak arc called day -1,-2, -3 etc. and the days 
following the day of the LH peak are called +1, +2, +3 etc. The follicular phase is 
defined as the period from the first day of menstruation to day -3. The periovulatory 
phase include days -2 to +1 and the luteal phase is defined as the period from day +2 
until the day before the next menstruation. The time sequenced data of a hormone 
throughout the menstrual cycle is called a 'response curve'. 
Because of the schedule of blood sampling (i.e. every other day) it can be expected 
that during the follicular and luteal phase half of the samples have been collected on the 
even days and the other half of the samples on the odd days. If one would connect the 
calculated mean values of a given hormonal parameter of every sampling day of the 
cycle, an artificial saw-edged curve might originate from this, as a result of the random 
division of the women into the 'even day' and 'odd day' groups. To avoid this artificial 
saw-edged patterns of hormonal parameters in serum, two successive days have been 
taken together during the follicular and luteal phase. In case of two serum samples taken 
incidently on both days, only the hormonal results of the second sample was disgarded. 
Thus all data for a given day are equally weighed in the analysis.Table II.8 gives a 
survey of the number of patients with a serum sample at the indicated day of the cycle 
and the chosen grouping of the samples. This table also shows the collected number of 
saliva samples on each day of the cycle. In the follicular phase the median value of the 
saliva measurements of day -12 to -3 have been used for statistical analysis. In the 
periovulatory phase the first or only values on days -2 and -1, and on days 0 and +1, 
PHASE OF THE MENSTRUAL CYCLE 
FOLLICULAR PERI- LUTEAL 
OVULATORY 
-12-11 • 10-9 -8-7 -6 -5 4 -3 
first or only value 
12-11-10-9 -8 -7 -6 -5 -4 -3 
median 
-2 -1 0 t-1 
only value 
-2 -1 0 +1 
first or 
only value 
+2+3 4+5 +6+7 +8+9 1-10+11 1-12+13 
first or only value 
+2+3+4+5 -6+7+8+9 1-10+11+12+13 
median 
Figure 2.2 Grouping of the hormonal data of serum and saliva for statistical analysis 
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respectively, have been used. In the luteal phase the median values of the periods +2 to 
+5, +6 to +9 and +10 to +13 have been used. Figure 2.2 summarises the grouping of the 
hormonal data of saliva and serum for statistical analysis. 
In the figures of the hormonal parameters as shown in chapter 3 and 4 the mean ± the 
standard error of the mean (SEM) of each hormonal parameter is plotted against the 
moment of the menstrual cycle, whereby the cycle is divided into periods in the way 
described above i.e. -12/-11; -10/-9; -4/-3; -2; -1; 0; +1; +2/+3; +4/+5 +12/+13. 
2.7.2 Statistical analysis 
To compare the hormonal patterns (=response curves) of each of the two infertile groups 
with the control group, the distribution-free statistical test described by Koziol et al.13 
has been used. This test is suitable in the comparison between response curves of two or 
more groups when incomplete observations are present and where parametric models 
for hormonal response curves are not available. This test has been performed separately 
for each of the three phases of the investigated menstrual cycle (follicular, peri-
ovulatory and luteal). 
In case the distribution of the hormonal parameter is not dependent on the day of the 
cycle the differences between the values of the infertile and control group have been 
analysed with the Wilcoxon (two sample) test based on the median value for each 
patient. 
The Wilcoxon test proceeds as follows: The observations, the concentrations of a 
hormone of a defined moment of the cycle, are ranked from low to high. Each patient of 
the total study population is given a rank, from 1 to 55. For each group the mean rank is 
calculated. The difference between two mean ranks is the Wilcoxon coefficient (un-
paired case). Group 1 is higher than group 2 means that the mean rank of group 1 is 
higher than the mean rank of group 2. In case of more observations during the cycle 
(response curve) for each group the sum of the mean ranks is calculated. Group 1 is 
higher than group 2 means that the sum of the mean ranks of group 1 is higher than the 
sum of group 2. The test is now called the test of Koziol and the sum of the ranks refer 
to an appropriate table of critical levels. This test is sensitive for differences between 
groups, which are in the same direction, i.e. always higher during the menstrual cycle. 
The level of significance selected is 5 percent 
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Table Π.8 Survey of the grouping of the serum and saliva samples of one menstrual 
cycle for the three investigated groups. The first column of each group shows the 
collected number of samples for each day of the cycle. The second column of each 
group gives, for the defined periods of the cycle, the number of samples used for 
analysis. 
Cycle 
day 
-12 
-11 
-10 
-9 
-8 
-7 
-6 
-5 
-4 
-3 
-2 
-1 
0 
+ 1 
+ 2 
+ 3 
+ 4 
+ 5 
+ 6 
+ 7 
+ 8 
+ 9 
+10 
+11 
+12 
+13 
SERUM 
Control Irregular Unexplained 
Group Cycles Infertility 
n=20 n=15 n=20 
7 11 4 9 4 10 
4 5 7 
10 19 7 14 11 18 
9 7 10 
9 18 5 11 8 16 
13 7 8 
11 19 8 12 11 17 
15 7 8 
11 17 11 14 11 20 
15 11 14 
15 15 12 12 14 14 
17 17 12 12 17 17 
19 19 14 14 18 18 
15 15 12 12 18 18 
18 18 6 12 15 19 
9 9 16 
12 18 6 14 9 18 
8 8 10 
6 18 5 12 8 16 
12 7 8 
6 19 6 12 10 15 
14 6 5 
4 13 6 13 13 19 
9 7 7 
7 13 7 11 9 17 
6 4 9 
SALIVA 
Control Irregular Unexplained 
Group Cycles Infertility 
n=20 n=l5 n=20 
2 20 3 13 0 13 
1 0 2 
6 2 1 
2 4 1 
2 4 1 
9 3 2 
7 1 4 
3 4 6 
5 5 2 
9 2 7 
7 14 8 10 10 16 
8 2 7 
9 15 5 8 8 9 
6 3 4 
6 16 5 10 4 18 
3 3 6 
8 3 7 
2 3 7 
4 18 3 10 3 14 
6 3 4 
3 2 8 
5 2 2 
3 13 3 9 4 15 
7 4 4 
4 2 4 
1 0 3 
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CHAPTER 3 
ENDOCRINOLOGICAL PARAMETERS OF THE 
GROUP WITH IRREGULAR CYCLES COMPARED TO 
THE CONTROL GROUP 
3.1 INTRODUCTION 
Ovarian dysfunction is a major cause of infertility. Approximately 30% to 40% of 
female infertility patients present with this problem, (see for review 1) An irregular 
cycle is not necessarily an anovulatory and/or an infertile cycle. Even though ovulation 
can occur in menstrual cycles of long duration, its relative infrcquency decreases the 
chances for conception. Abnormal menstrual cycles can also have a negative effect on 
the target organs for sex steroids, e.g. the cervical mucus, and this may represent an 
indirect cause of infertility. 
Deviations of the normal pattern of the menstrual cycle can be caused by various 
factors. Dysfunction can occur at hypothalamic, pituitary or ovarian level, it can be due 
to systemic diseases or thyroid or adrenal dysfunction. 
A meaningful therapeutic approach to female infertility due to insufficient menstrual 
cycles is completely dependent on a adequate diagnostic evaluation. Both careful 
medical history and BBT records are helpful in assessing the pattern of the menstrual 
cycle. However, usually these methods neither give clues to the cause of an eventual 
abnormality, nor to the therapeutic approach for the infertility problem. 
In order to evaluate the role of various endocrine parameters in the abnormal 
menstrual cycle and to see if hormonal determinations could reveal the cause of cycle 
disturbance, frequent sampling of serum was carried out in 15 women with abnormal 
menstrual patterns. During the same cycles saliva was also collected for determinations. 
The concentrations and cyclical patterns of the steroid levels in serum and saliva were 
compared. The results of the infertile women with irregular menstrual cycles were 
compared with data obtained from normal ovulating women, who were supposed to be 
fertile. 
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Figure 3.1 Serum levels of LH, FSH, LH/FSH ratio and prolactin during one 
menstrual cycle of 15 women with irregular cycles (dotted line) and 20 fertile women 
(drawn line). (Mean ± SEM) 
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3.2 RESULTS 
3.2.1 Endocrinological parameters in serum 
3.2.1.1 LH, FSH and the LHIFSH ratio (Fig 3.1) 
Figure 3.1 presents the patterns of LH, FSH and the LH/FSH ratio of the group with 
irregular cycles (dotted line) and the control group (drawn line). During the whole cycle 
the levels of LH tended to be higher in the women with irregular cycles in comparison 
to the control group, especially during the follicular (p= 0.06) and periovulatory phases 
(p=0.09). 
The FSH levels of the women with irregular cycles were slightly lower than in the 
fertile women, but this difference never reached statistical significance. 
As a result of the slightly increased LH- and low-normal FSH-concentrations, the 
LH/FSH ratio was elevated in the group with irregular cycles in comparison to the 
normal women, (follicular phase, p=0.02, periovulatory phase, p=0.05 and luteal phase, 
p= 0.09). For both groups the LH/FSH ratios were higher in the luteal phase compared 
to the follicular phase. 
3.2.1.2 Prolactin (Fig 3.1) 
During the follicular phase a tendency existed to higher prolactin levels in the women 
with irregular cycles (p=0.07). In the periovulatory and luteal phases no significant 
difference was found between the control group and the group with irregular cycles. 
Some women with irregular cycles showed elevated prolactin levels during the luteal 
phase. These findings are responsable for the wide range of prolactin concentrations 
during this period in this group which explains the lack of statistical difference between 
the two groups. 
Individual observations 
Eight women of the control group incidentally showed a prolactin concentration above 
800mIU/L, the upper limit of normal in our laboratory, and three women had elevated prolactin 
levels on four, six and seven occasions, respectively, during the investigated cycle. None of the 
prolactin concentrations of the women of the control group exceeded 1500 mlU/L, and the length 
of their cycles was within the normal range. The mean concentration of prolactin of each woman 
during her studied cycle was under 800m lU/L except for one woman who had a mean prolactin 
level of 896 mlU/L. 
In the group with irregular cycles, four women occasionally showed a prolactin concentration 
above 800 mIU/1 and four women mostly had elevated prolactin levels throughout the observed 
menstrual cycle. The mean prolactin levels of the latter four women were 907, 1094, 1243 and 
1435 mlU/L, respectively. They all received bromocriptine treatment for at least 6 months and 
three of these women conceived whilst on this treatment. 
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Figure 3.2 Serum levels of 17ß-oestradiol, progesterone, 17a-OH-progesterone and 
androstenedione during one menstrual cycle of 15 women with irregular cycles (dotted 
line) and 20 fertile women (drawn line). (Mean ± SEM) 
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3.2.1.3 17ß-Oestradiol(Fig3.2) 
In both groups the midcycle LH surges were preceded by 17ß-oestradiol peaks. In most 
women the highest level of 17ß-oestradiol was found on cycle day -1 and in a minority 
the highest LH and 17ß-oestradiol concentration coincided on the same day. The 
maximum level of 17ß-oestradiol in the luteal phase was on day +8/+9 in both groups. 
In each corresponding phase no statistical difference in 17ß-oestradiol levels was 
found between the group with irregular cycles and the control group. 
3.2.1.4 Progesterone (Fig 3.2) 
No significant differences in progesterone levels were found between the women with 
irregular cycles and the women with normal menstrual cycles. In both groups the first 
day of significant increase in progesterone concentration, i.e. an elevation of more than 
twice the inter-assay variability, was on cycle day 0 or on the day before, cycle day -1. 
The maximal level of progesterone in the luteal phase was on day +8/+9 in the group 
with irregular cycles and on day +6/+7 in the control group. 
3.2.1.5 17a-OH-Progesterone (Fig 3.2) 
During the follicular phase of the cycle, the levels of 17a-OH-progesterone were almost 
constant and not different in both groups. During the periovulatory phase the 17a-OH-
progesterone concentrations in the group with irregular cycles tended to be higher than 
in the control group (p=0.07).In both groups a significant increase of the 17a-OH-
progesterone level was found on the day of the LH peak or on the day preceding the LH 
surge. In both groups a small 17a-OH-progesterone peak was seen coincident with the 
LH peak. 
During the luteal phase a second rise appeared with maximal levels between days +4 
and +9 in both groups. 
3.2.1.6 Androstenedione (Fig 3.2) 
The androstenedione concentrations of the women with irregular cycles tended to be 
higher in comparison to the concentrations of the women with normal cycles but this 
difference was not significant. Figure 3.2 shows no clear cyclical pattern, neither in the 
control group nor in the group with irregular cycles. However, considering the 
individual woman the highest concentration of androstenedione was mostly detected 
during the periovulatory phase of the cycle. 
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Figure 3J Serum levels of testosterone, DHEA, DHEAS and Cortisol during one 
menstrual cycle of 15 women with inegular cycles (dotted line) and 20 fertile women 
(drawn line). (Mean ± SEM) 
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3.2.1.7 Testosterone (Fig 3.3) 
Throughout the observation period total testosterone concentrations were mostly higher 
in women with irregular cycles, (follicular phase p=0.05, periovulatory phase p=0.09 
and luteal phase p=0.21) In the women with irregular cycles no obvious cyclical pattern 
of testosterone levels was seen: individual women demonstrated highest testosterone 
concentrations at different phases of their cycles. In the control group the highest 
testosterone concentration was mostly determined during the periovulatory phase and 
also, the lowest testosterone concentration was never seen during this period. 
3.2.1.8 DI1EA, DHEAS (Fig 3.3) 
As for the DHEA and DHEAS concentrations, no difference between the two groups, 
and no cyclical pattern was found. 
3.2.1.9 Cortisol (Fig 3.3) 
The Cortisol concentrations of both groups were not different. Neither in the women 
with irregular cycles, nor in the normal women a cyclical pattern of Cortisol was seen. 
3.2.1.10 SHBG and Free Androgen Index 
In four women of the control group and in one woman with an irregular cycle SHBG 
was determined throughout the whole cycle. None of these five women showed a 
cyclical pattern for SHBG. In the remaining women of the control group and the group 
with irregular cycles SHBG was determined once in the very early follicular phase. The 
median concentration of early follicular SHBG in both groups was 50 nmol/L. The 
concentrations in the group with normal cycles ranged from 34 to 93 nmol/L and in the 
group with irregular cycles from 13 to 98 nmol/L. The free androgen index (FAI, i.e. the 
ratio of total serum testosterone to SHBG multiplied by 100) did also not differ between 
the two groups either and ranged from 1.51 to 10.3 in the control group and from 1.79 
to 11.5 in the women with irregular cycles. 
Individual observations 
One woman in the control group had high serum testosterone concentrations (range 2.7 to 4.5 
nmol/L) and also a high FAI (10.3), nevertheless she had normal menstrual patterns and no hyper-
androgenic symptoms. 
The woman with an irregular cycle and a FAI of 11.S had normal serum testosterone levels 
(range 1.5 to 2.7, median 2.2 nmol/L). Her early follicular SHBG concentration was 13 nmol/L; 
her serum 17ß-oestradiol levels during the early follicular period were normal. 
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Figure 3.4 Saliva levels of 17ß-oestradiol, progesterone, 17a-OH-progesterone and 
androstenedione during one menstrual cycle of 15 women with irregular cycles (dotted 
line) and 20 fertile women (drawn line). (Mean ± SEM) 
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3.2.2 ENDOCRINOLOGICAL PARAMETERS IN SALIVA 
32.2.1 17ß-Oestradiol(Fig3.4) 
No significant difference was found in the concentrations of saliva 17ß-oestradiol 
between the control group and the group with abnormal cycles. Neilhcr was there a 
difference in the ratio of saliva to serum oestradiol between the two groups. 
Because of the limited number of saliva samples, no conclusions can be drawn on the 
cyclical pattern of 17ß-oestradiol in saliva. The saliva 17ß-oestradiol peaks on days -1 
and +1 in the group with irregular cycles (sec figure 3.4) are probably artefacts, caused 
by the low number of samples taken on the days mentioned above. 
3.2.2.2 Progesterone (Fig 3.4) 
A clear cyclical pattern was seen in saliva progesterone levels synchronously to that of 
the serum levels. The highest progesterone concentrations were seen between days +4 
and +9. No difference in saliva progesterone levels were found between the two groups. 
An increase in progesterone concentration just prior to ovulation could not be 
demonstrated in saliva. 
3.2.2.3 17a-OH-Progesterone (Fig 3.4) 
17a-OH-Progesterone concentrations in saliva were higher in the women with irregular 
cycles in comparison to the normal women. During the luteal phase this difference was 
statistically significant (p=0.02). In both groups a cyclical pattern could be recognised. 
A small peak during the periovulatory phase was seen in saliva as well as in serum. 
3.2.2.4 Androstenedione (Fig 3.4) 
The group with abnormal menstrual cycles had higher androstenedione levels in 
comparison to the control group (^=0.08). The highest saliva androstenedione 
concentration was mostly found during the periovubtory period. 
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Figure 3.5 Saliva levels of testosterone, DHEA, DHEAS and Cortisol during one 
menstrual cycle of 15 women with irregular cycles (dotted line) and 20 fertile women 
(drawn line). (Mean ± SEM) 
Data were arranged according to the deviations of the LH peak (= day 0) 
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3.22 J Testosterone (Fig 35) 
The saliva concentrations of testosterone were markedly elevated in the women with 
irregular cycles in comparison to the control group (^=0.003). 
Due to the limited number of observations, no conclusions could be drawn on the 
presence or absence of a cyclical pattern of testosterone in saliva. 
5.2.2.6 DHEA,DHEAS(Fig35) 
The concentrations of both hormones, DHEA and DbŒAS, were higher in the group 
with abnormal cycles compared to the control group (p= 0.04 and p=0.12, respectively), 
but no cyclical pattern was present. 
5.2.2.7 Cortisol (Fig 35) 
The saliva Cortisol concentrations did not differ significantly between the two groups. 
41 
Table Ш.1 P-values of the comparison of the collected hormonal data 
of the group with irregular cycles versus the control group. (Statistical 
test described by Koziol). 
For comparison of 17-OHP, A-dione, testosterone, DHEA, DHE AS and 
Cortisol in saliva the median value of the whole menstrual cycle was 
used. 
Phase of the cycle: 
Follicular Periovulatory Luteal 
SERUM: 
LH 
FSH 
LH/FSH ratio 
Prolactin 
17tt-Oestradiol 
Progesterone 
17-OHP 
A-dione 
Testosterone 
DHEA 
DHEAS 
Cortisol 
SHBG 
FAI 
SAUVA: 
Oestradiol 
Progesterone 
17-OHP 
0.06 
0.71 
0.02 
0.07 
0.26 
0.37 
0.23 
0.16 
0.05 
0.79 
0.94 
0.67 
0.46 
0.88 
0.85 
0.95 
0.40 
0.13 
0.47 
0.05 
0.36 
0.73 
0.47 
0.07 
0.60 
0.09 
0.85 
0.79 
0.37 
0.47 
0.21 
0.80 
0.29 
0.16 
0.09 
0.40 
0.25 
0.59 
0.15 
0.70 
0.21 
0.31 
0.63 
0.51 
0.18 
0.83 
0.02 
Menstrual Cycle 
SAUVA: 
A-dion 0.08 
Testosterone 0.003 
DHEA 0.04 
DHEAS 0.12 
Cortisol 0.19 
3.3 DISCUSSION 
In the present investigation hormonal data were collected throughout one menstrual 
cycle of 15 infertile women with irregular cycles and 20 normally menstruating women. 
Before the investigation all women of the study group had irregular cycles, either of 
too short (n=2) or of too long a duration (n=13). During the study the cycle lengths were 
within the normal range in seven women and were more than 32 days in eight women. 
This difference in cycle lengths before and during the investigation illustrates the 
irregular nature of the menstrual cycles of this group. In other investigations only a 
small variation within subjects was demonstrated, however, these referred to normally 
menstruating women.2·3 
All study cycles were ovulatory as confirmed by an LH surge and postovulatory pro-
gesterone concentrations above 15 nmol/L. 
The LH concentrations and LH/FSH ratios of the group with irregular cycles tended 
to be higher than in the control group, especially during the follicular and periovulatory 
phase of the cycle. 
Furthermore the serum testosterone levels were in a higher range in the earlier phases 
of the cycle in the women with irregular cycles. The salivary androgens were also 
elevated in the group with irregular cycles in comparison to the normally menstruating 
women. It is reported that plasma testosterone levels are directly correlated with a 
significant prolongation of the follicular phase and that elevated androgen levels can 
indeed result in ovarian dysfunction.4 
Some women in the control group also showed slightly elevated serum testosterone 
levels. These small elevations of testosterone were associated with slightly elevated 
serum DHEA and/or DHEAS concentrations and normal androstenedione concentra-
tions. This indicates the source of androgen production to be the adrenals. In contrast, 
the elevated serum testosterone levels in the women with irregular cycles were mostly 
combined with elevations of androstenedione without an increase in serum DHEA and 
DHEAS concentrations. This finding suggests that the source of most androgen 
secretion in women with irregular cycles is the ovary. 
Elevated LH and low or normal FSH values and excess androgen production are 
characteristic features of polycystic ovarian disease (PCOD).5"7 In response to the 
elevated LH levels, theca and stroma cells secrete increasing amounts of androstene-
dione and testosterone. The aromatising capacity of C-19 steroids of the granulosa cell 
layer in polycystic ovaries is reduced due to insufficient FSH stimulation.8 FSH 
deficiency and increased intraovarian androgen concentrations inhibit normal follicular 
maturation.9 
However, the 17ß-oestradiol concentrations of the study group of women with 
irregular cycles were not different from those of the regularly menstruating females. 
Serum 17ß-oestradiol levels represent the sum of 17ß-oestradiol production derived 
from secretion by the ovary and from peripheral conversion of androgens to oestrogens. 
In the women of this study an increase in extraglandular oestradiol production may be 
compensated by a decrease of granulosa cell aromatising capacity. 
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In this study elevated LH levels and excess of androgen production have been 
demonstrated in women with irregular cycles. However, this hormonal status did not 
result in anovulation. It is possible that the women in this group suffer from a mild, sub-
clinical or early form of PCOD characterised by infertility and endocrinological features 
of PCOD, but without anovulation. Also the classical manifestation of obesity was 
absent in the women of this study, since the Quetelet index was in the normal range and 
did not differ from those of the control group. The etiology of PCOD is still a matter of 
debate. It has been proposed by Schwartz et al10 to consider PCOD as a gradually 
developing pathophysiological process. In this view the women in this study can be 
considered as having early forms of PCOD. 
The biological activity of androgens is dependent on the amount of unbound, freely 
circulating hormone.11·12 The level of SHBG is viewed as a major determinant in the 
control of the physiologically effective plasma levels of androgens and oestrogens. Tes-
tosterone is bound to SHBG and albumin for 99% and only 1% circulates freely in 
blood. Androgens suppress the production of SHBG, thus potentiating the biological 
activity of androgenic steroids.13 The production of SHBG is, on the contrary, increased 
by oestrogens. 
It has been reported that the free androgen index, i.e. the ratio of serum testosterone 
to SHBG, is a more sensitive parameter of hyperandrogenism.14 However, the women 
with irregular cycles showed a wide range of SHBG concentrations and FAI's. In the 
women with irregular cycles as well as in the control group the FAI seemed to correlate 
with the saliva testosterone concentrations, although this relation was not significant. It 
is assumed that the concentration of a steroid in saliva represents the unbound, 
biologically active part of that hormone.15·16 In this investigation no direct correlation 
was found between hormone determinations in serum and saliva, neither in the women 
with normal cycles, nor in the women with irregular cycles. The variation in the ratio 
serum to saliva concentrations of a steroid was rather large. Although not always at the 
same moment, all serum and saliva samples were obtained between 8:00 and 12:00 
hour. Thus, the variation in saliva samples cannot be explained by a circadian rythm. 
The possibility should not be excluded that in pathological circumstances a discrepancy 
exists between the free fraction of a steroid, as represented by the steroid concentration 
in saliva, and the total amount of a steroid (serum concentration). This means that the 
proportion of unbound steroid in pathological circumstances can be different from that 
in normal conditions. 
The Cortisol levels of the women with irregular cycles were similar to those of the 
control women, which indicated the absence of hypercortisolism. 
The plasma levels of progesterone and 17a-OH-progesterone, a derivate of pro-
gesterone, were stable during the follicular phase within the range of 2.5 to 3.0 nmol/L. 
A significant rise of both progestins was seen prior to the LH peak in serum and saliva. 
This is in agreement with other investigators who reported that an increasing secretion 
of progesterone and 17a-OH-progesterone just prior to the LH peak may indicate one of 
the earliest changes associated with luteinisation of the follicle and the approaching 
ovulation.17"19 This parallel rise in progesterone and 17a-OH-progesterone appeared in 
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normally menstruating women and in the women with irregular cycles. The rise of pro­
gesterone persisted and reached maximal levels on day +6/+7 in the control group and 
on day +8/+9 in the group with irregular cycles. However, 17a-OH-progesterone 
concentrations showed a peak coincident with the LH peak with a small decline 
thereafter. Following this event a second peak was found during the midluteal phase. 
Periovulatory 17a-OH-progesterone concentrations tended to be higherin the women 
with cycle irregularities. The periovulatory 17a-OH-progesterone peak was also 
demonstrated in saliva. This small periovulatory 17a-OH-progesterone peak confirms 
other investigations.20·21 However, these reports made no comment on the decline of 
17a-OH-progesterone levels after the LH surge. Probably the LH peak itself or the 
event of the ovulation is the cause of the decline in 17a-OH-progesterone on day +1. It 
might be the expression of the termination of the Δ 5 pathway of oestrogen synthesis and 
the initiation of the Δ4 pathway. 
In both groups the progesterone levels tended to increase until later in the luteal 
phase and showed an abrupt decline there after, whereas 17a-OH-progesterone concen­
trations reached the maximum level earlier. 
When comparing the prolactin levels of the group with irregular cycles with those of 
the control group, no statistical differences were found in any of the three periods of the 
cycle. A tendency existed towards higher prolactin concentrations in the follicular 
phases of the women with irregular cycles. In the women with irregular menstrual 
cycles a large variation was seen in prolactin levels both within one subject as well as 
between the subjects. This wide range of prolactin concentrations was most obvious 
during the luteal phase. It has been demonstrated that prolactin levels tend to be higher 
during the luteal phase than during the early follicular phase.2 2 '2 5 These differences in 
prolactin secretion probably reflect an altered hypothalamic neurotransmission during 
the luteal phase.26 
Four women with irregular cycles can be assigned as hyperprolactinaemic, although 
not in all samples of their study cycles the prolactin concentration exceeded the upper 
limit of normal of 800 mlU/L. The pregnancies that were established in three of these 
four women very soon after initiation of bromocriptine treatment are not an absolute 
proof but very suggestive of an infertility associated with transient or intermittent 
elevated prolactin levels. Bromocriptine normalises elevated prolactin levels with 
concommittant restoration of ovarian function.27 
More than 50% of the women with irregular cycles and 40% of the control group 
showed an elevated prolactin concentration at least once during the investigated period. 
On the other hand, the four women assigned as hyperprolactinaemic also showed occa­
sionally prolactin concentrations within the normal range. This proves the need for at 
least two or three prolactin determinations in an infertility investigation program, as 
prolactin elevation can be intermittent. A single elevated level does not confirm 
pathology and a single normal value does not exclude iL 
Excessive prolactin secretion is frequently associated with anovulation and amenor­
rhoea. Despite the increased prolactin levels found in both groups, the investigated 
cycles were all ovulatory. Even the four women assigned as hyperprolactinaemic had 
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ovulatory cycles during the study, and in one of them the cycle was of normal duration 
(31 days); the three other hyperprolactinaemic women were oligomenorrhoeic. None of 
the hyperprolactinaemic women showed any sign of a defective luteal phase as their 
luteal phases ranged from 14 to 17 days with progesterone levels within the considered 
normal luteal phase range. 
The mechanisms by which prolactin exerts its effect on the fertility of these women 
is not fully clear. Secondary causes, such as hypothyroidism, medication, and renal or 
hepatic failure, have been excluded. 
Hyperprolactinaemia can disturb the hypothalamic-pituitary-ovarian axis at several 
levels. Prolactin can act at the hypothalamic level by inhibiting the GnRH secretion and 
hence by disturbing the gonadotrophin release. Pituitary responsiveness to GnRH is 
normal in such women and a normal pattern of gonadotrophin pulsatile secretion is 
restored with small, repetitive doses of GnRH.28 The baseline LH levels can be in the 
normal range in hyperprolactinaemic women, but without or with an altered pulsati-
lity.29 This can also result in anovulation and/or amenorrhoea. Leyendecker et al30 
demonstrated that ovulation can be induced in women with hyperprolactinaemic 
amenorrhoea when pulsatile LH secretion is re-established by the administration of 
intermittent exogenous LHRH, despite persistent elevation of prolactin concentrations. 
At the pituitary level hyperprolactinaemia decreases the positive feedback of 
oestrogen on gonadotrophin release.31 However, ovarian response to exogenous gona-
dotrophin stimulation is maintained in hyperprolactinaemic amenorrhoea. Caro and 
Woolf32 were able to show that the oestradiol elevation following the gonadotrophin 
surge induced by exogenous LHRH was not different in normal and hyper-
prolactinaemic women.) Hyperprolactinaemia can cause inhibition of ovarian activity 
by a direct inhibitory action of prolactin on the ovary. Prolactin can impair human luteal 
function. Some studies reported a shortening of the hyperthermic phase and a reduction 
in progesterone synthesis by the corpus luteum.33-35 Other investigators, however, could 
not demonstrate this negative effect of prolactin on the luteal phase.36 
Hyperprolactinaemic patients may represent heterogenous groups with different degrees 
of hypothalamic disorder. Probably the transient hyperprolactinaemia and the relatively 
mild elevation of prolactin in the women in this study was not sufficient to interfere 
with follicular maturation, ovulation, or corpus luteum function, but it may impair 
fertilisation and/or implantation. This confirms another report37 which suggested that 
transient hyperprolactinaemia apparently does not disturb ovulation or luteal function 
but acts on targets other than the hypothalamic-pituitary-ovarian axis, such as ovum 
fertilisation or embryo implantation. 
No direct relation could be demonstrated between the prolactin levels and the 
androgen levels. For every woman, including the four women with frequently elevated 
prolactin levels, the Kendall-coefficient of correlation was determined between prolac-
tin and DHEAS on one hand and prolactin and testosterone on the other hand. No 
statistical correlation was found either between prolactin and DHEAS nor between 
prolactin and testosterone. Several studies have suggested an association between 
hyperprolactinaemia and high levels of DHEAS.3840 However, other investigators have 
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been unable to confirm this.41·42 Even inverse relationships between prolactin levels 
and both DHEAS and testosterone levels have been reported.43 
In summary, the observations presented provide a detailed picture of the hormonal 
events in serum and saliva in women with normal and in women with irregular 
menstrual cycles. Menstrual irregularity cannot be regarded as a pathophysiological 
entity and ovulatory dysfunction may be caused by different etiologic factors. The 
fifteen women who formed the study group showed relatively small differences in endo-
crinological parameters to the control group. However, two major cycle disturbances 
could be recognised: early or mild forms of PCOD and transient hyperprolactinaemia. I 
lean therefore be concluded that the evaluation of irregular menstrual cycles must be 
directed to the diagnosis or exclusion of these disturbances. FOT the detection of 
hyperandrogenism salivary testosterone is a usefull tool. Since transient hyperprolac-
tinaemia may be difficult to diagnose, repeated sampling should be performed during 
the luteal phase before a conclusion can be drawn whether this is present or not. 
This study also shows the existence of a gradual transition from normal menstrual 
cycles through mild PCOD or transient hyperprolactinaemia to obvious cycle distur-
bances such as amenorrhoea caused by frank PCOD or hyperprolactinaemia. 
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CHAPTER 4 
ENDOCRINOLOGICAL PARAMETERS OF 
THE GROUP WITH UNEXPLAINED INFERTILITY 
COMPARED TO THE CONTROL GROUP 
4.1 INTRODUCTION 
The diagnosis unexplained infertility is established in couples in whom complete and 
intensive investigation and up to date medical examination fail to reveal any cause for 
their childlessness. The better the understanding of the physiology of reproduction and 
the more advanced the diagnostic approach, the less frequently this unsatisfactory 
diagnosis has to be used, (see for review 1-4) The incidence of unexplained infertility 
depends on the limits of evaluation and medical knowledge. During the last 20 years 
considerable progress has been made in the diagnosis of causes of infertility. Therefore 
the incidence of unexplained infertility has declined from approximately 80% of 
infertile couples to 5% to 10%. 
The incidence also depends on the criteria used to define normality and abnormality. 
Sometimes infertility despite correction of the factor(s) identified as responsible for 
infertility, (e.g. normalisation of the menstrual cycle by ovulation inducing drugs or 
treatment of endometriosis) is considered as unexplained infertility.2 
The results of various, often empirical, therapies (e.g. clomiphene citrate5 and 
bromocriptine6) used for these couples suggest abnormalities in the endocrine patterns 
of the cycle. However, the results of such studies are of little value if not compared with 
the pregnancy rates in series of untreated couples in a prospective manner, since the 
spontaneous pregnancy rate for couples with unexplained infertility without any 
treatment is reported to be 36% to 87%.7-9 
Subtle endocrinological disorders have been detected in women in whom no cause 
for infertility could be found.10"15 Such disorders, if present, may only be detected by 
detailed endocrine profiles. In this study an extensive endocrinological assessment was 
performed in women from couples with unexplained infertility after the routine 
screening procedure. Because of the uncertainty about the limits of normal variation of 
the different hormones and the ranges which can be considered with confidence to 
indicate a normal ovulatory cycle, the results were compared with the hormonal data 
obtained in women with presumed normal fertility. 
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Figure 4.1 Serum levels of LH, FSH, LH/FSH ratio and prolactin during one 
menstrual cycle of 20 women with unexplained infertility (dotted line) and 20 fertile 
women (drawn line). (Mean ± SEM) 
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4.2 RESULTS 
4.2.1 Endocrinological parameters in serum 
4.2.1.1 LH. FSH and the LHIFSH ratio (Fig 4.1) 
Figure 4.1 shows the patterns of LH, FSH and the LH/FSH ratio of the group with 
unexplained infertility (dotted line) and the control group (drawn line). The LH concen-
trations were significantly higher during the follicular phase in the women with 
unexplained infertility in comparison to the control group (p=0.02). During the periovu-
latory phase also a tendency existed to higher LH concentrations in the group with 
unexplained infertility (p=0.09). An earlier onset of the LH surge in the women with 
unexplained infertility is seen in figure 4.1 in comparison to the control group. No 
statistically significant difference in LH levels between the two groups was found in the 
luteal phase of the cycle. 
The FSH levels and the LH/FSH ratios of the group with unexplained infertility were 
not statistically different from those of the control group. 
In both groups the LH levels during the luteal phase were higher than during the 
follicular phase, whereas the FSH levels were lower during the luteal phase. 
4.2.1.2 Prolactin (Fig 4.1) 
No statistical difference was found in prolactin levels between the group with 
unexplained infertility and the control group. 
Individual observations 
Eleven women with unexplained infertility and also eleven fertile women showed incidentally an 
increased prolactin level (>800 mlU/L). However, no women of the fertile group showed 
prolactin levels above 1500 mlU/L, whereas in five women with unexplained infertility prolactin 
levels exceeded 1500 mlU/L at least once. Six women with unexplained infertility showed 
elevated prolactin concentrations on four or more occasions during the investigation. All women 
with transient elevated prolactin levels had a nonnal cycle length during the investigation. The 
mean prolactin concentration of the investigated cycle of three women with unexplained 
infertility exceeded the upper limit of nonnal in our laboratory of 800 mlU/L. Three women with 
transient hyperprolactinaemia became pregnant, one of whom after bromocriptine treatment. 
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Figure 4.2 Serum levels of 17ß-oestradiol, progesterone, 17a-OH-progesterone and 
androstenedione during one menstrual cycle of 20 women with unexplained infertility 
(dotted line) and 20 fertile women (drawn line). (Mean ± SEM) 
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4.2.1.3 17ß-Oestradiol(Fig4.2) 
The 17ß-oestradiol levels were higher during the follicular phase in the women with 
unexplained infertility (p=0.04). 
The cyclical pattern of 17ß-oestradiol in the group with unexplained infertility was 
similar to that of the control group with a maximum concentration on cycle day -1 or 0 
and a luteal peak on cycle day +8/+9. 
4.2.1.4 Progesterone (Fig 4.2) 
The progesterone levels were not statistically different in either of the three phases of 
the cycle. The first significant rise of progesterone was on the day previous to the LH 
peak (cycle day -1) in both groups. The progesterone peak was on day +8/+9 in the 
women with unexplained infertility and on day +6/+7 in the control group. 
4.2.1.5 17a-OH-Progesterone (Fig 4.2) 
The 17a-OH-progesterone levels of the two groups were in the same range and were 
not statistically different. The first significant increase in 17a-OH-progestcrone 
concentrations advanced the LH surge by one day in both groups. Also a small 17a-
OH-progesterone peak was seen on day 0 in both groups, and a second peak in the 
luteal phase preceding the progesterone peak. 
4.2.1.6 Androstenedione (Fig 4.2) 
The androstenedione levels of the group with unexplained infertility were significantly 
higher only during the luteal phase (p=0.05). No clear cyclical pattern for 
androstenedione was seen in either of the two groups. When the women were 
considered individually, the highest concentration of androstenedione was usually found 
during the periovulatory period. 
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Figure 4.3 Serum levels of testosterone, DHEA, DHEAS and Cortisol during one 
menstrual cycle of 20 women with unexplained infertility (dotted line) and 20 fertile 
women (drawn line). (Mean ± SEM) 
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4.2.1.7 Testosterone (Fig 4.3) 
Figure 4.3 suggests lower testosterone levels in the women with unexplained infertility 
compared to the control group, but this difference was not statistically significant. 
In the individual woman of both groups the highest testosterone concentration was 
seen usually during the periovulatory phase and the lowest concentration during the 
luteal phase. 
4.2.1.8 DHEA and DHEAS (Fig 4.3) 
During the luteal phase DHEA levels tended to be lower in the women with 
unexplained infertility in comparison to the control group (p=0.09). No cyclical pattern 
in DHEA and DHEAS concentrations was seen. 
4.2.1.9 Cortisol (Fig 4.3) 
No differences between the two groups were found in serum Cortisol levels. The Cortisol 
concentrations did not differ throughout the menstrual cycle. 
4.2.1.10 SHBG and the FAI 
In one woman with unexplained infertility and four fertile women SHBG was deter­
mined throughout the whole cycle: there was no obvious cyclical pattern. In the other 
patients SHBG was determined in the very early follicular phase. SHBG concentrations 
in the group with unexplained infertility ranged from 30 to 130 nmol/L and from 34 to 
93 nmol/L in the control group. The median concentrations were 69 and 50 nmol/L 
respectively. 
The FAI, i.e. the ratio of total serum testosterone to SHBG χ 100, ranged from 1.28 
to 9.12 in the group with unexplained infertility and from 1.51 to 10.3 in the control 
group. The median FAIs were 2.76 and 3.90 respectively. 
Individual observations 
Two women with unexplained infertility with mean serum testosterone concentrations of 2.49 and 
2.87 nmol/L (high-normal) respectively, and SHBG levels of 30 and 34 nmol/L (low-normal) and 
high FAb (8.0 and 9.12 respectively), had high serum DHEA and DHEAS concentrations 
throughout the whole cycle. 
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Figure 4.4 Saliva levels of 17ß-oestradiol, progesterone, 17a-OH-progesterone and 
androstenedione during one menstrual cycle of 20 women with unexplained infertility 
(dotted line) and 20 fertile women (drawn line). (Mean ± SEM) 
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42.2 ENDOCRINOLOGICAL PARAMETERS IN SALIVA 
4.2.2.7 17ß-Oestradiol (Fig 4.4) 
The concentrations of 17ß-oestradiol in saliva were raised in the women with 
unexplained infertility compared to the fertile women (follicular phase: p=0.03, peri-
ovulatory phase: p=0.15 and luteal phase: p=0.004). 
The maximum concentration of saliva IVß-oestradiol was found on cycle day -1 in 
both groups. Only in the group with unexplained infertility a second peak appeared on 
day +6/+7 of the luteal phase. 
4.2.2.2 Progesterone (Fig 4.4) 
There was insufficient evidence for a significant difference in saliva progesterone levels 
between the two groups. The progesterone levels in saliva in the women with 
unexplained infertility tended to be lower during the periovulatory period (p=0.07). In 
both groups a cyclical pattern was seen similar to that of progesterone in serum. 
However, no significant increase of progesterone previous to the LH peak was recogni-
sed in saliva. 
4.2.2.3 17a-OH-Progesterone (Fig 4.4) 
No statistical difference was found in 17a-OH-progesterone levels between the group 
with unexplained infertility and the control group. The cyclical pattern in saliva was 
similar to that in serum with a clear midluteal peak concentration. In the women with 
unexplained infertility also a peak was found on day 0, like in serum. In the control 
group a periovulatory peak was also detected, but the maximum concentration was 
detected on the day after the LH peak, day +1. 
4.2.2.4 Androstenedione (Fig 4.4) 
Neither a difference between the two groups, nor a cyclical pattern was found for the 
saliva androstenedione concentrations. 
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Figure 4.5 Saliva levels of testosterone, DHEA, DHEAS and Cortisol during one 
menstrual cycle of 20 women with unexplained infertility (dotted line) and 20 fertile 
women (drawn line). (Mean ± SEM) 
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4.2.2.5 Testosterone (Fig 45) 
The saliva concentrations of testosterone of the women with unexplained infertility 
tended to be higher in comparison to the fertile women (p=0.06). Neither in the control 
group nor in the group with unexplained infertility a cyclical pattern could be recogni-
sed. 
4.2.2.6 DHE A and DHE AS (Fig 4 J) 
The levels of DHEA and DHEAS in saliva were not different for the two groups. 
4.2.2.7 Cortisol (Fig 45) 
Cortisol concentrations in saliva were in the same range in women with unexplained 
infertility and fertile women. 
Table IV.l Ρ-values of the comparison of the collected hormonal data 
of the group with unexplained infertility versus the control group. 
(statistical test described by Koziol). 
For comparison of 17-OHP, A-dione, testosterone, DHEA, DHEAS and 
Cortisol in saliva the median value of the whole menstrual cycle was 
used. 
SERUM: 
LH 
FSH 
LH/FSH ratio 
Prolactin 
Oestradiol 
Progesterone 
17-OHP 
A-dione 
Testosterone 
DHEA 
DHEAS 
Cortisol 
SHBG 
FAI 
SAUVA: 
Oestradiol 
Progesterone 
17-OHP 
SALIVA: 
A-dione 
Testosterone 
DHEA 
DHEAS 
Cortisol 
Follicular 
0.02 
0.38 
0.43 
0.18 
0.04 
0.31 
0.48 
0.95 
0.51 
0.21 
0.65 
0.67 
0.27 
0.32 
0.03 
0.18 
0.61 
Phase of the cycle: 
Menstrual 
0.27 
0.06 
0.67 
0.56 
0.34 
Periovulatory 
0.13 
0.42 
0.77 
0.87 
0.69 
0.30 
0.82 
0.73 
0.65 
0.77 
0.11 
0.42 
0.15 
0.07 
0.82 
Cycle 
Luteal 
0.57 
0.72 
0.53 
0.68 
0.16 
0.61 
0.25 
0.05 
0.09 
0.09 
0.24 
0.35 
0.004 
0.27 
0.56 
4.3 DISCUSSION 
Serum and saliva hormonal parameters of 20 women with unexplained infertility were 
collected during one menstrual cycle. The data were compared with a control group. 
Normal main parameters in a fertility workup program were used to select the group 
with unexplained infertility. It can be expected that this group is not homogeneous, 
since many mfertility problems, both of male and female, are not fully elucidated. In the 
case of unexplained infertility minor abnormalities in either male or female reproduc-
tive function can very well be present 
In spite of the selection criterion of regular menstrual cycles of normal duration 
between 26 and 34 days, three women had a cycle length of 24 days and two women 
had an oligomenorrhoea with an interval of 39 and 63 days, respectively, during the 
investigated period. Fifteen women with unexplained infertility had a normal cycle 
length during the same period. 
All women suffering from unexplained infertility had an ovulatory cycle, as could be 
confirmed both by sufficiently elevated progesterone levels during the luteal phase and 
by ultrasound monitoring of the cycle. In all females follicle growth and the disap-
pearance of the follicle was seen ultrasonographically. This finding makes a luteinised 
unruptured follicle (LUF) syndrome very unlikely. Luteinisation of an unruptured 
follicle is characterised by normal endocrinologie patterns and a biphasic BBT. Failure 
of follicle rupture has been demonstrated to occur more frequently in unexplained 
infertility.16 
In the extensive investigation of the hormonal characteristics of the females of 
couples with unexplained infertility a wide range of individual prolactin concentrations 
was found, which was not clearly related to the stage of the cycle or to any other of the 
reproductive hormones. Six women demonstrated elevated prolactin levels on four or 
more occasions. These females can be considered as having intermittent or transient 
hyperprolactinaemia. The pregnancies that resulted after treatment of transient hyper-
prolactinaemia with bromocriptine, as described in chapter 3 and also in one woman 
with unexplained infertility treated with bromocriptine, indicate the possibility of 
transient hyperprolactinaemia as a cause of infertility. 
Hyperprolactinaemia as a cause of, or in association with, amenorrhoea and anovula-
tion has been well documented.17 In contrast, consistently elevated prolactin levels or 
transient hyperprolactinaemia in combination with regular, ovulatory menstrual cycles 
have also been reported.18·22 However, prolactin concentrations have been shown to be 
signifícantly lower in conception than in non-conception cycles.23 The effect of 
transient hyperprolactinaemia on menstrual cycle and on fertility and the importance of 
this phenomenon are not exactly known. 
Infertility in normally menstruating women associated with hyperprolactinaemia has 
been attributed to luteal phase deficiency, which is a reflection of a follicular disorder.24 
According to Nakano18 hyperprolactinaemia in infertile women with regular menstrual 
cycles was associated with defects in follicle development, as measured by oestradiol 
production during the mid-follicular phase, but not with reduced corpus luteum 
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function. Glazener et al.21 also found no evidence of luteal phase insufficiency in infer-
tile women with normal menstrual cycles and hypcrprolactinaemia. Furthermore, the 
chance of conception was not related to the prolactin levels. The women with transient 
elevated prolactin levels in this investigation also showed no evidence of luteal phase 
insufficiency as assessed by luteal progesterone concentrations and the duration of the 
luteal phase. 
High prolactin levels may also be due to the presence of immunoreactive molecular 
forms that are biologically inactive in vivo, such as 'big.big' prolactin.25 The molecular 
heterogeneity may be the explanation for the absence of pathological effects in some 
patients with apparent elevated levels of scrum prolactin. 
Bromocriptine has been used to treat women with unexplained infertility,6 but one 
controlled study has denied any affect.26 Ben-David and Schenker27 found in 94% of 
women with regular menses and longstanding idiopathic infertility a transitory elevation 
of their serum prolactin levels. Treatment with bromocriptine resulted in a pregancy rate 
of 40%. They concluded that this transitory, relatively mild hypcrprolactinaemia was 
not sufficient to interfere with follicular maturation, ovulation, or corpus luteum 
function, but it would impair fertilisation and/or implantation. Transient hyperprolactin-
aemia may be considered as the presentation of an early phase in the natural evolution 
of hyperprolactinaemic amenorrhoea.20 
It also follows from these observations that in all infertile women, including those 
with unexplained infertility, prolactin concentration should be determined on at least 
two occasions. 
The usefulness of treatment of this abnormality is not clear. Properly controlled 
prospective therapeutic trials with dopamine agonistic drugs like bromocriptine in 
normally menstruating women with transient hyperprolactinaemia are required. 
The LH levels of the women with unexplained infertility were higher compared to 
the LH concentrations of the control group during the follicular phase. During the 
periovulatory phase a tendency existed towards higher LH levels in the women with 
unexplained infertility. The preovulatory rise of LH concentrations started earlier in the 
women with unexplained infertility in comparison to the control group. Serum FSH 
levels and the LH to FSH ratios did not differ between the two groups. The normal FSH 
levels in the women with unexplained infertility provide the development of follicular 
growth, but the accelerated onset of the LH surge may result in an early preovulatory 
luteinisation of the follicle. The early luteinisation of the follicle is not confirmed by 
serum progesterone levels, but periovulatory levels of saliva progesterone tended to be 
elevated in the women with unexplained infertility. A similar observation was reported 
from a study of PCOD patients treated with LHRH, who had elevated LH levels and 
normal FSH levels in the follicular phase and both nonnal LH and FSH concentrations 
during the luteal phase.28 
Another explanation for the contribution of high follicular phase LH concentrations 
to infertility may be a direct effect on maturation of the oocyte itself. A significant 
reduction in the fertilisation rate and failure of implantation of embryos in an in vitro 
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fertilisation and embryo transfer program was observed in women who demonstrated 
elevated LH levels in their follicular phase.29 
The 17ß-oestradiol concentrations of the group with unexplained infertility were also 
elevated in the follicular phase of the study cycle. Furthermore, saliva 17ß-oestradiol 
levels were statistically significantly elevated during the follicular and luteal phases of 
the investigated cycle. The elevated 17ß-oestradiol values can be interpreted as a result 
of the elevated LH concentrations. In response to the increased LH levels, the thecal 
cells are stimulated to produce androgens, which can then be converted to oestrogens in 
the granulosa cells, through FSH-induccd aromatisation. The testosterone concentra-
tions in saliva, which correlate well with the free fraction of testosterone,30 tended to be 
higher in the women with unexplained infertility. The excessive free testosterone 
concentrations serves as substrate for peripheral conversion of testosterone to 17ß-
oestradiol by extra-glandular tissue. 
The high saliva 17ß-oestradiol concentrations, which are supposed to represent the 
free, biologically active part of 17ß-oestradiol,31"33 detected in the women with 
unexplained infertility may inhibit ovum transport after fertilisation and thereby causing 
infertility. In the hamster it was observed that oviductal contractility is related to 
oestradiol and through that influences ovum transport to the uterus.34 Contractions of 
the oviduct start as soon as the 17ß-oestradiol levels decline. 
After IVF and ET procedures it was demonstrated that the progesterone to oestrogen 
ratio during the luteal phase was a better predictor of implantation than the absolute 
concentration of either hormone.35"37 In mice implantation was inhibited by relatively 
high levels of 17ß-oestradiol.36 
Serum concentrations of androstenedione, testosterone and DHEA tended to be lower 
during the luteal phase of the cycles of the women with unexplained infertility. 
Nevertheless, the testosterone concentration in saliva of the women with unexplained 
infertility tended to be higher throughout the investigated cycle. Measurement of 
salivary testosterone gives a useful indication of levels of biologically available andro-
gen.38 A highly significant correlation between the concentration of testosterone in 
saliva and the concentration of unbound testosterone in plasma has been demonstrated, 
both in normal and in hyperandrogenic patients.39 However, Wang et al.40 reported that 
the free testosterone index (= the free androgen index) was a better discriminator of 
hyperandrogenism. 
The increased secretion of LH, the elevated testosterone concentrations in saliva and 
the subsequent increased levels of 17ß-oestradiol in women with otherwise unexplained 
infertility, may be associated with a suboptimal menstrual cycle that prevents the 
initiation of a pregnancy. 
Despite two normal semen analyses before entrance to the investigation, six men of 
couples with unexplained infertility had a slightly abnormal SA and four men showed 
severe abnormalities in their SA. In the control group nine SAs were performed and 
four men had an abnormal spcrmiogram. No uniform agreement exists about the lower 
limits of a normal semen analysis. It is not certain when a semen sample, presumed to 
be normal, is also fertile. From several studies it is concluded that there is a significant 
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overlap between the sperm characteristics of men known to be fertile and those 
presumed to be infertile.41"44 The combination of all variables of the standard SA has a 
better predictive value in the investigation of infertility than each of the separate charac-
teristics.43 Low values, however, provided stronger indication of poor fertility. Standard 
semen analysis does not necessarily describe function. At present there is no simple in 
vitro method by which the in vivo fertilising capacity of sperm can be reliably 
measured. The SPA in this study also provided no absolute criterium of fertility and 
infertility, since only four men in the fertile group (n=8) had a positive SPA. Fourteen 
males of couples with unexplained infertility had a positive SPA. Eight males of the 
group with unexplained infertility had a completely normal SA, a sufficient motility 
after preincubation and a positive SPA. The remaining twelve men had at least one 
abnormality in the investigations of the semen sample. No absolute conclusions about 
one's fertility potential can be drawn from the results of the conventional SA and the 
SPA, since both fertile men demonstrated abnormalities in SA and SPA and infertile 
men can have a normal SA and SPA. 
The criteria for the diagnosis of unexplained infertility as used in our clinic closely 
resemble that of the definitions proposed by others. Despite this, 90% (18/20) of the 
couples classified as having unexplained infertility before entrance into the investiga-
tion, showed, after extensive investigation, subtle abnormalities in the female's hormo-
nal secretory pattern and/or in the male's investigation of the ejaculate. It is, however, 
uncertain wether these abnormalities are responsable for their infertility. 
This study shows once more how unsatisfactory it is to diagnose an infertility as 
unexplained. With intensive investigations of the hormonal parameters at the proper 
moments in the menstrual cycle and with repeated, detailed and well standardised 
analysis of the semen propably 90% of the so-called unexplained infertility can be 
explained. It is to be hoped and expected that the remaining 10% will disclose an 
explanation in the near future. 
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CHAPTER 5 
HUMAN CHORIONIC GONADOTROPHIN (hCG) 
MEASUREMENTS IN THE LUTEAL PHASE OF THE 
MENSTRUAL CYCLE OF INFERTILE 
AND FERTILE WOMEN 
(Partly published in Human Reproduction 3: 219-221,1988) 
5.1 INTRODUCTION 
There is evidence that women trying to conceive have a high incidence of early 
conceptual loss in the luteal phase of the menstrual cycle. In 1952 Hertig et al.1 
examined 34 fertilised human ova recovered during the first 17 days after conception 
from uteri removed from fertile women. They found that 13 fertilised ova (38%) were 
morphologically abnormal and could not have resulted in a normal pregnancy. On the 
basis of a statistical model Roberts and Lowe2 postulated that most of the human con-
ceptions are lost and only 22% of the conceptions lead to the birth of a child. Biggcrs3 
estimated the probabilities of conception, recognisable pregnancy and live birth. He 
calculated a probability of fertilisation of an ovum of 0.84, and a probability of a 
recognisable pregnancy of 0.42. By the time pregnancy is recognised, half the embryos 
are lost. The probability of a live birth is 0.31. 
Other studies47 reported on the presence of human chorionic gonadotrophin (hCG) 
in the luteal phase of the menstrual cycle as the only evidence of pregnancy without a 
delay of the menstrual period. These studies all related to normally fertile women. It is 
not clear yet whether unrecognised pregnancy wastage occurs in women with 
unexplained infertility and it is unknown whether this phenomenon is of importance as 
a cause of unexplained infertility. 
The purpose of the present study is to investigate the possible occurrence of early 
conceptual loss in women with unexplained infertility by measuring hCG levels in 
serum during the luteal phase. The results are compared with the levels of a control 
group of assumed fertile women. 
5.2 MATERIALS AND METHODS 
5.2.1 Selection of females with unexplained infertility 
Twenty women of couples suffering from unexplained infertility with a duration of 12 
months or more formed the study group. The mean duration of their infertility at the 
time of the investigation cycle was 37.5 months (SD 19.4, range 12 - 72 months). They 
had regular menstrual cycles of 26 - 32 days with biphasic BBT charts and a luteal 
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phase of at least 12 days with sufficiently elevated progesterone levels. The husband's 
semen analysis was normal on at least two occasions (>20 χ IO6 sperm cells per mL, 
£50% with good forward progression and <40% abnormal forms). The postcoital test 
was positive and no abnormalities were demonstrated during hysterosalpingography and 
/or during laparoscopy. None of the patients received treatment during this study. 
5.2.2 Selection of the control group 
The control group consisted of 20 volunteer women who were either parous or who had 
no reason to doubt their fecundity and who were attempting to conceive. Conditions for 
admission in the control group were regular menstrual cycles of 26 to 32 days, no 
pregnancy during 3 months preceding the study cycle, trying to conceive during at most 
6 months and no suspicion on pathology interfering with fertility. The groups were 
comparable regarding age. 
5.2.3 Detection of ovulation 
Follicular growth and ovulation was monitored by ultrasound every day from day 10 of 
the menstrual cycle onwards. The day a follicle of at least 18 mm had disappeared was 
supposed to be the day of ovulation. In the group with unexplained infertility daily 
serum LH measurements took place. The day after the maximal LH level (LH-peak) 
was supposed to be the day of ovulation. The day of ovulation was called day 0. 
5.2.4 Schedule of blood sampling 
Blood samples were collected by vena puncture and were taken every other day starting 
on the 4 ^ or 5* day after ovulation. Sampling was continued until the next menstru­
ation or until pregnancy was confirmed. 
5.2.5 Determinations of hCG 
Three different immunoassay procedures were used: a two-component Radio-
ImmunoAssay (RIA) for hCG which detects both intact hCG and the free ß-subunit of 
hCG ('total hCG'), a free hCG-ß specific RIA ('free hCG ß-subunit") and an Immuno 
EnzyMetric Assay (IEMA) specific for the intact hCG molecule ('intact hCG"). A 
survey of the characteristics of the three assays is given in table V. 1. The two RIAs have 
been developed in our laboratory and have been described earlier.8 The IEMA is a 
commercially available assay system (Tandem-Ε hCG, Hybritech Europe S.A., Liege, 
Belgium) using monoclonal antibodies. 
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Table V.l Analytical characteristics of the hCG immunoassay systems 
Assay Reference Results Analytical Clinical Intra-assay Inter-assay 
sensitivity sensitivity coefficient coefficient 
of variation of variation 
Total hCG 1«IRP ng/mL* 0.7 2.0 7.3 12.0 
FreehCG 1«ΠΙΡ-β mIU/L** 50 100 6.3 9.3 
ß-subunit 
Intact hCG 2^15, lU/L 2.5 2.5 3.3 6.3 
1st IRP 
* 1 ng/mL = 15IU/L (l»' IRP-hCG) = 0.23 IU/L (1« IRP-hCG-ß) 
2 ng/mL = 34 IU/L (1" IRP-hCG) = 0.41 IU/L (1« IRP-hCG-ß) 
** 1st IRP-hCG-ß: Ing = ImlU, by definition 
5.3 RESULTS 
None of the women with unexplained infertility became pregnant during the 
investigation. The duration of their luteal phases (from 11 to 17 days) was in the normal 
range. 
Five presumed fertile women became pregnant during the study cycle and delivered 
all from healthy children. The remaining 15 women of this group menstruated on the 
12lh to the 16th day after ovulation. 
5.3.1 Total hCG 
Three patients of the group of unexplained infertility demonstrated detectable serum 
total hCG during the luteal phase. The first woman showed this on the lo* day after 
ovulation, the day her menstrual period started; the second woman on days 6, 9 and 13 
after ovulation and the third woman on the 8th and 10th day after ovulation. In this 
group no woman achieved a clinical pregnancy and no total hCG values were found 
above 1.9 ng/mL. 
In 18 of the 20 fertile women total hCG was detected at least on one occasion in the 
luteal phase. In 13 of these 20 assumed fertile women elevated total hCG values were 
found in the luteal phase followed by a normal menstruation (table V.2). Five fertile 
women achieved a clinical, ongoing pregnancy (fig 5.1). These were all singleton 
pregnancies, confirmed by ultrasound. In two females no hCG levels were found above 
1 ng/mL. 
The elevated total hCG values showed no consistent pattern. In two women total 
hCG was already detected on the 4th day after ovulation. In one woman a total hCG 
level of 2.8 ng/mL was measured on the 15th day, the same day her menstruation began. 
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Serum hCG (ng/ml) 
Я*—? 1 1 1 1 1 1 г 
10 12 H 16 
days after ovulation 
Figure 5.1 Measurements of Total hCG during the luteal phase of five women with 
clinical, ongoing pregnancies 
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Table V.2 Maximal total hCG, free hCG ß-subunit and intact hCG values in the luteal 
phase of the menstrual cycle of 20 assumed fertile women and 20 women with unex-
plained infertility. 
Infertile (n=20) Fertile (n=20) 
Total hCG (ng/mL) 
<1.0 
1.0-1.9 
£2.0 
Free hCG ß-subunit (mlU/L) 
<100 
à 100 
Intact hCG(IU/L) 
<2.5 
>2.5 
* 5 clinical pregnancies 
53.2 Free hCG ß-subunit 
Only in one woman with unexplained infertility not only elevated total hCG 
concentrations but also detectable free hCG ß-subunit levels were detected. Further-
more, in four other infertile women free hCG ß-subunit was detected during the luteal 
phase, however, only on one occasion in each woman. 
In the fertile group two of the 13 women with elevated total hCG values without a 
delay in menstruation, showed elevated free hCG ß-subunit levels on at least one 
occasion. In 10 women no free hCG ß-subunit was detected despite elevated total hCG 
levels. In the five women with clinical pregnancies free hCG ß-subunil was detected in 
the luteal phase, but the first day of detection of total hCG always preceded the first day 
of detection of free hCG ß-subuniL (table V.3) 
In both groups no correlation was found between the actual values of total hCG and 
free hCG ß-subunit. 
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2 
9 
9* 
15 
5 
11 
9+ 
18 
2 
14 
6* 
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10 
12 
5 
5 
11 
(11)* 
16 
15 
14 
15 
14 
12 
10 
12 
11 
9 
Table V.3 First day of detection of hCG in the luteal phase of five 
women with clinical, ongoing pregnancies (day 0 = ovulation) 
First post-ovulatoiy day of detection of 
Total hCG Free hCG Intact hCG 
Patients ß-subunit 
A-3 
A-9 
A-14 
A-16 
A-20 
* The day of a second rise of detectable hCG is given between brackets 
On one occasion, after an initial rise, hCG decreased below the detection level and 
showed a second increase which continued. 
5.3.3 Intact hCG 
In two women with unexplained infertility intact hCG was detected during the luteal 
phase. 
In the fertile group intact hCG was detected in five women with clinical pregnancies. 
The first day of detection of intact hCG is given in table V.3. Furthermore in one 
presumed fertile woman a concentration of 3.2 IU/L intact hCG was detected on the 
11* ¿ay after ovulation, despite a normal menstrual cycle. The concentrations of intact 
hCG of the two infertile women and one fertile woman who had elevated intact hCG 
levels without a delay of their menstrual periods, were 1/4 to 1/10 of those in the preg-
nant women on the corresponding days. 
5.4 DISCUSSION 
Evidence for the existence of very early conceptual loss is documented by several 
methods: morphological, statistical, and biochemical. HCG is a very reliable marker of 
early pregnancy.9 Although it is known from in vitro studies that the blastocyst itself is 
capable of producing hCG before implantation,10·11 it is assumed that hCG appears in 
maternal blood at the time of implantation, at around 8-9 days after ovulation.12·13 A 
rise in plasma hCG reflects the presence of a functional trophoblast and thereby 
confirms the existence of a probable pregnancy.14 
Problems exist in the determination of hCG. The early detection of hCG depends on 
the degree of analytical sensitivity of the assay (i.e. the lowest detectable concentration 
of hCG), while the specificity of an hCG immunoassay depends to a great extent on the 
antibodies used, with little cross-reaction of components with structural similarities. An 
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ideal assay has a high sensitivity, i.e. it is able to quantify very low hCG concentrations, 
and has also a high specificity, i.e. it does not detect hCG when no hCG is present. The 
hCG molecule consists of a hormone-nonspecific a-subunit and a hormone-specific 
ß-subunit, synthesised separately.15·16 The a-subunit is almost identical to the a-sub-
unils of Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH), and Thyroid 
Stimulating Hormone (TSH). The amino acid sequence of the hCG-ß subunit bears 80% 
similarity to that of the LH-ß subunit. Immunochemical assays for the detection of hCG 
make use of specific antibodies against the ß-subunit or against the intact hCG 
molecule. The first RIA used in this study applies an antiserum against hCG-ß and is 
designated a two-component assay, since it detects both the whole hCG molecule and 
the free hCG-ß subunit ('total hCG').8 In other reports similar two-component assays 
were called TiCG-ß', a name which creates confusion. Furthermore hCG was determined 
by a specific RIA which detects the free ß-subunit only and an IEMA for the 
determination of the intact hCG molecule. 
An additional problem in the immunochemical measurement of hCG is the determi-
nation of biologically inactive but immunoreactive components circulating in the blood, 
such as the precursors and metabolites of hCG, or degraded hormone fragments. 
Furthermore, confusion is brought about by the unstructured use of the three different 
reference standards, i.e. the 1st IRP-hCG, the 1st IRP-hCG-ß, and the 2nd IS. The use of 
different hCG assays and different reference standards make it difficult to compare 
various reports about early hCG detection. 
If the lower limit of 1.0 ng hCG/mL would be considered the definition for concep-
tion, in this study, three of 20 patients with unexplained infertility (15%) and 13 of 20 
presumed fertile women (65%) showed early conceptual loss, whereas the probability of 
fertilisation in the fertile group was 0.90 (18/20). The studies of Biggers3 and Roberts 
and Lowe2 showed similar data, although based on other methods. However, when the 
cut-off value of total hCG was considered 2.0 ng/mL, no early conceptual losses were 
found in the infertile group and four early conceptual losses were seen in the fertile 
group. This is in agreement with the study of Sharp et al17, who found that 'apparent' 
early conceptual loss in non-pregnancy cyles was associated with eventual fertility. 
Although the clinical sensitivity of the total hCG RIA is 2.0 ng/mL the difference in 
the number of women with total hCG levels more than 1.0 ng/mL in the two groups is 
surprising. This difference cannot be explained by cross reaction of LH. In both groups 
the LH concentrations were in the normal range of the luteal phase, and no statistically 
significant differences could be shown between the two groups studied. However, these 
assumed early conceptual losses could not be confirmed by the assay of free hCG ß-
subunit nor by the assay of intact hCG. 
The hCG IEMA which detects only intact hCG, has a very high specificity. This 
assay shows no cross reaction with LH, FSH, or TSH or with the free ß-subunit of hCG. 
The analytical and clinical sensitivity of this assay are both 2.5 IU/1. Biochemically the 
determination of intact hCG would be the most indicative method to demonstrate con-
ception. In the five fertile women with clinical, ongoing pregnancies intact hCG was 
detected before their missed period. In one fertile woman and two infertile women intact 
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hCG was demonstrated, but in much lower concentrations. Based on the assumption 
that the determination of intact hCG is the most appropriate method to detect 
conception at an early stage, one early conceptual loss was seen in the fertile group and 
two women in the infertile group showed this phenomenon. 
Variable quantities of intact hCG and of free subunits have reported to be present in 
pregnancy sera and the sera of patients with gestational trophoblastic disease.18-20 The 
mechanism of regulation of hCG production in early pregnancy is largely unresolved. It 
has been suggested in an earlier repon21 that a difference might exist between the 
immunologic and biologic activities of hCG. Further study is required to investigate the 
relationship between intact hCG, free hCG ß-subunit and other bioactive and/or 
immunoreactive hCG compounds to explain the apparently conflicting results in the 
most early stage of pregnancy. Furthermore, heterogeneity of both the circulating a and 
β subunits has been demonstrated.22 
In none of the studies on early conceptual loss intact hCG was determined, and the 
assumptions of early conceptual loss were based on assays which make use of 
antibodies against the ß-subunit of hCG and thus detect both the whole hCG molecule 
and the free ß-subunit. 
The first day of detection of hCG in the three different assays of this study did not 
agree with each other. The assays of 'total hCG' and 'intact hCG' were more sensitive in 
early detection of hCG than the assay of the free ß-subunit. The range in first day of 
detection of hCG in the luteal phase in case of clinical pregnancy was high. (fig. 5.1) 
Since this difference cannot be explained on biological or biochemical grounds, this 
indicates even more the need for very cautious interpretation of the results of different 
hCG measurements. 
In view of these findings it is highly possible that the frequency of early conceptual 
loss based on hCG(-ß) determinations only, is overestimated. Early conceptual loss after 
implantation of the conceptus forms no major explanation for unexplained infertility. 
The assays of total hCG and intact hCG are useful markers for the detection of the 
fertilised ovum around the time of implantation. However, these tests cannot detect 
earlier loss of the ovum. New methods for earlier detection of pregnancy have been 
developed,23 and their usefulness in clinically unrecognised early pregnancy loss should 
be investigated. 
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CHAPTER 6 
ZONA-FREE HAMSTER OVUM SPERM 
PENETRATION ASSAY 
6.1 INTRODUCTION 
In the investigation of male fertility attention is mainly paid to the classical semen 
parameters: volume, density, motility and morphology. The conventional semen analysis 
(SA) gives more information on the quantity of morphologically normal, well moving 
spermatozoa than on their functional capacity. 
Supplementary information on sperm quality can be obtained by the in vitro sperm 
mucus penetration meter (SPM) test according to the method of Kremer.1 This assay 
evaluates the capacity of spermatozoa to penetrate into human cervical mucus in vitro. 
In vivo the sperm cells migrate into the uterus and Fallopian tubes through active 
movement to reach the oocyte. The spermatozoa acquire their fertilising capacity during 
their ascent in the female genital tract.2 This process is called capacitation. The next 
essential event for spermatozoa to penetrate the surrounding layers of the ovum is the 
acrosome reaction. A spermatozoon that has passed through the zona pellucida of the 
oocyte fuses with the egg plasma membrane, the vitellus, and the sperm nucleus with 
chromatine décondensâtes and develops into a sperm pronucleus. The sperm pronucleus 
then fuses with the egg pronucleus: the actual conception takes place. Until recently it 
was impossible to determine the fertilising capacity of spermatozoa in the routine 
fertility work up of the male. With the introduction of the zona pcllucida-frce hamster 
ovum sperm penetration assay (SPA), a more direct test for the evaluation of the 
fertilising capacity of human spermatozoa became available.3 After washing and 
preincubation of the ejaculate, the spermatozoa are incubated together with zona-free 
hamster oocytes and finally the eggs are examined on sperm penetration. A positive 
SPA means that the sperm cells are capable to capacitate, to undergo the acrosome 
reaction, to enter and fuse with the vitelline membrane and to undergo the initial stages 
of nuclear decondensation.4·5 However, a positive result of the SPA does not always 
mean that the investigated male is fertile.6 In order to achieve conception in vivo the 
spermatozoa must traverse the cervical mucus and forward motility is required to ascend 
in the female genital tract to reach the site of fertiUsation. Furthermore the 
spermatozoon has to pass the zona pellucida. This function of the sperm cells is not 
determined in the SPA, for the surroundings of the ova are removed from the hamster 
oocytes. On the other hand, a negative SPA does not necessarily reflect the inability of 
spermatozoa to fertilise human oocytes in vivo.7'9 
Since the introduction of the SPA, over 300 publications have appeared on this 
subject The widespread use of the test has created controversies about the usefulness 
and value of the SPA as an additional parameter of the fertility investigation. The 
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outcome of the SPA is influenced by many variables. A crucial factor in the interpreta-
tion of the result is the viability and the motility of the spermatozoa after the in vitro 
capacitation process.10 
In this investigation the correlation between motility after preincubation and the 
outcome of the SPA has been studied. Furthermore the influence of two different 
methods of sperm washing on the motility after preincubation and on SPA results are 
considered. The correlations between SPA and routine semen parameters, between SPA 
and SPM-test and between SPA and IVF results are reported and discussed. 
6.2 CORRELATION BETWEEN THE ZONA-FREE HAMSTER 
OVUM SPERM PENETRATION ASSAY AND THE 
CONVENTIONAL SEMEN ANALYSIS PARAMETERS 
6.2.1 Introduction 
Routine SA is the most conventional method to obtain knowledge on male fertility. In 
1677 Antoni van Leeuwenhoek was probably the first person to observe spermatozoa in 
the human ejaculate.11 During especially the last three decades research on semen has 
made a remarkable progress and the SA has become routine in the male fertility investi-
gation. The main parameters of the SA are density, motility, and morphology. The 
conventional SA proceeds from the assumption that conception in vivo will result if 
there is a certain critical number of motile and morphologically normal spermatozoa in 
the ejaculate. Routine SA gives information on the quantity rather than on the quality of 
the semen. The SPA has been advocated as a qualitative assay for the evaluation of the 
fertilising ability of human spermatozoa. A survey of the literature of the SPA shows 
controversies about the correlations between the SA and the SPA.(see for review 4,5,12) 
In order to determine whether the presence of impaired penetrating capacity can be 
predicted from the routine SA, the conventional semen parameters were considered 
versus the SPA results. 
6.2.2 Materials and methods 
6.2.2.7 Patients 
The study group consisted of 220 males of infertile couples. The men were not further 
divided into infertile, subfertile and potentially fertile, because infertility frequently 
cannot be assigned with certainty to either partner of an infertile couple. In all couples 
the involuntary infertility existed for at least one year. Only one semen sample from 
each man was used for the study. 
6.2.2.2 Semen analysis 
After at least 48 hours of sexual abstinence semen samples were produced by 
masturbation and collected in a sterile container. The samples were allowed to liquefy 
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for 30 to 60 minutes at room temperature. The ejaculates were analysed within two 
hours after collection. Each semen sample was examined with the use of conventional 
techniques for determinination of semen volume, sperm density, percentage of motile 
spermatozoa, motility grade and percentage of morphologically normal spermatozoa. 
The grade of motility was expressed in a motility score: 1: immobile, 2: poor, 
3: moderate, 4: fairly good, 5: good, 6: excellent. 
Semen characteristics were considered to be normal with a sperm density of at least 
20 χ lOfymL, at least 50% motile spermatozoa (two hours after collection), motility 
grade at least 4, and 40% or less morphologically abnormal spermatozoa. If one or more 
of these parameters were outside the normal range, the semen sample was considered to 
be abnormal. 
Screening on sperm antibodies was performed by the Mixed-Antiglobulin-Reaction 
(MAR) test which makes use of antihuman IgA and IgG antibodies linked to polyacryl 
amide beads (Bio Rad Laboratories BV, Utrecht, The Netherlands).13 None of the 
samples included in this study showed evidence of agglutination or a positive MAR-
test. 
6.2.2.3 Zona-free hamster ovum sperm penetration assay 
A part of the liquefied semen sample was diluted with Biggers-Whitten-Whiltingham 
(BWW) medium14 to 10 mL and cenirifuged at 300 g for 5 min. The supernatant was 
removed and afterwards the pellet was washed twice again with BWW. The last pellet 
was rcsuspended in 0.5 to 2.0 mL BWW and adjusted to a final spermatozoal concentra­
tion of 5 to 10 χ lOfymL and transferred to Falcon tubes (Falcon Plastics 2063, Becton 
Dickinson Labware, Oxnard, Ca 93030). The tubes were placedhorizontally in an air 
incubator at ЗТХ for 18 to 20 hours in order to effect capacitation. 
The oocytes were collected from female golden hamsters (Mesocricetus auratus), 
which were induced to superovulate with human menopausal gonadotrophin (HMG, 
Humegon®, Organon, Oss, The Netherlands) and human chorionic gonadotrophin 
(hCG, Pregnyl®, Organon, Oss, The Netherlands). The corona radiata was dispersed by 
bringing the oocytes in a hyaluronidase solution (Hyason®, 150 U/mL, Organon, Oss, 
The Netherlands). The zona pellucida was removed with 0.1% bovine pancreatic trypsin 
(type ΙΠ, Sigma Chemical Co). After washing of the oocytes with BWW (3 mg/mL 
serum albumin) three times, the zona-free hamster oocytes were placed in Falcon petri 
dishes (Falcon Plastics 3001, Becton Dickinson Labware, Oxnard, Ca 93030) con­
taining 0.3 mL BWW (30 mg/mL serum albumin) and covered with paraffin. Unlike 
other studies the SPAs were performed with approximately ten hamster oocytes. In an 
earlier, not yet published, experiment of 235 SPAs, it was proven that the penetration 
rate of SPAs calculated on 10 ova is not statistically different from the penetration rate 
of SPAs calculated on all available oocytes, varying from 11 to 30 (p=0.96). Also, the 
percentage of SPAs with at least one penetrated ovum was 52.7% when only the first 10 
ova were examined, whereas when all the ova were assessed this percentage was 60.6% 
(not significant). 
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The spermatozoa! suspension was added to the hamster ova and after an incubation 
period of two to three hours (37 0 Q the eggs were examined on sperm penetration. The 
presence of a swelling sperm head or pronuclei connected to a visible sperm tail in the 
cytoplasm was considered a positive assay for penetration. The penetration rate (in %) 
was defined as the number of penetrated oocytes divided by the total number of oocytes 
multiplied by 100. Penetration of at least one egg was considered a positive SPA. A 
negative SPA was defined as a penetration rate of 0%. 
6.2.2.4 Statistics 
The statistical comparison between percentages for two different groups was performed 
using the chi-square test for the 2 χ 2 table. The contingency coefficient was used as a 
measure for the strength of the dependence between two dichotomous variables. 
6.2.3 Results 
A positive SPA was found in 149 of the 220 samples (68%). A completely normal SA 
was determined in the samples of 104 men, of whom 86% had a positive SPA. The 
remaining 116 males had one or more abnormal semen characteristics, and 52% of this 
group had a positive SPA. 
Of the 220 semen samples 195 had a normal density and 25 had a density of less than 
20 χ lOfymL. Less than 50% motile sperm cells were seen in 32 samples; 188 had at 
least 50% motile spermatozoa. The grade of motility was moderate or less in 24 
samples and fairly good, good or excellent in 196 cases. In 117 ejaculates morpholo­
gical examination showed no more than 40% abnormal forms and in 103 semen 
samples more than 40% abnormal spermatozoa were seen. For each semen parameter 
the number and frequency of positive SPA scores are shown in table VI.l. The 
differences between the number of positive SPAs for a 'good' or for a 'not-good' semen 
parameter were always statistically significant. 
Table VI.l Frequency of positive SPAs in relation to the semen characteristics 
(n=220) 
Semen 
characteristic 
Density 
% Motility 
Motility grade 
Abnormal forms 
Category 
'not-good' 
<20 χ 106/mL 
6/25 
<50% 
13/32 
<4 
9/24 
>40% 
51/103 
Percentage 
pos. SPA 
24% 
41% 
38% 
50% 
Category 
'good' 
à20 χ lOtymL 
143/195 
>50% 
136/188 
¿4 
140/196 
<40% 
98/117 
Percentage 
pos. SPA 
73% 
72% 
71% 
84% 
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In the same way the mean penetration rates and the standard deviations in relation to the 
different semen characteristics are shown in table VI.2. The large standard deviations 
reflect the extensive variability in penetration rate over the different samples. It was also 
found that the more normal semen characteristics in the semen analysis were present, 
the more a positive SPA was seen. In the total group of 220 men 15 had 4 abnormal 
semen parameters. Only 2 men in this group had a positive SPA. 
Table VI.2 The mean penetration rates and standard deviations of 220 SPAs in 
relation to the semen characteristics 
Semen 
characteristic 
Category 
'not-good' 
Penetration 
rate (%±SD) 
Category 
'good' 
Penetration 
rate (%±SD) 
Density 
% Motility 
Motility grade 
Abnormal forms 
<20xl06/mL 
<50% 
<4 
>40% 
10 ±25% 
21 ± 14% 
17 ± 29% 
21 ±30% 
â20xl06/mL 
>50% 
>4 
<40% 
38 ± 36% 
37 ± 36% 
37 ± 37% 
47 ± 37% 
Up to now there is no agreement on the definition of a positive SPA. The limits mostly 
applied to define a positive SPA are a penetration rate of more than 0% or more than 
15%. To determine the most appropriate definition of a positive SPA the contingency 
coefficients between the different semen parameters and the SPA for two different 
dichotomisations, '0%' and '15%', respectively, have been assessed, (table VI.3) The 
contingency coefficient is used to express the strength of the relationship. It shows that 
all semen characteristics have the strongest correlation with the result of the SPA with a 
lower limit of positive SPA as more than ,0%,in comparison to a limit of '15%'. 
Table VI.3 Contingency coefficients between the different semen 
characteristics and the SPA for two definitions of positive SPA 
Semen characteristic 
DEFINmON OF POSITIVE SPA: 
Penetration rate>0% Penetration rate>15% 
Density 
Motility percentage 
Motility grade 
Morphology 
0.318 
0.233 
0.221 
0.343 
0.224 
0.176 
0.129 
0.291 
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6.2.4 Discussion 
The routine SA gives insufficient information on the actual function of the spermatozoa. 
The SPA has been advocated as a more direct test to assess the in vitro fertilising ability 
of human spermatozoa. 
To determine whether the SPA gives additional information in the fertility 
investigation of the male, the relation between the routine SA and the SPA is studied in 
a group of 220 men of infertile couples. Furthermore, the strength of the correlation 
between the outcome of the SPA and the classical semen characteristics for two 
different definitions of a positive SPA has been assessed. Allsemen parameters showed 
the best correlation with the SPA with a lower limit of penetration of 1 %. For that 
reason and because of the smaller number of ova used per assay (usually approximately 
ten) in comparison to other investigators, any sample with penetration at any level 
between 1% and 100% has been considered as a positive SPA. Several investigators 
have published on the range of penetration rates seen in 'fertile' and 'infertile' 
populations. The lower range of penetration for the fertile men varies between 0 and 
25%.6·8·9·15-22 The margin of difference between infertile and fertile men is not clear. 
The study group consists of infertile, subfertile and fertile men. It can be expected 
that in this group a large variation in SA values is seen. To detect a possible correlation 
between parameters of the SA and the SPA, a large variation in SA data is required and 
the group has not been divided into (sub)fertile and infertile subjects. 
It has been shown that the ability to penetrate hamster oocytes depends on whether or 
not the routine semen characteristics meet the criteria for normal semen analysis values 
(table VI.2). Every normal semen parameter showed a statistically significantly higher 
chance to contribute to a positive SPA compared with an abnormal semen parameter. 
Furthermore, the more normal semen parameters in the SA were present, the more 
males showed a positive SPA. In the study group as a whole a significant correlation 
was demonstrated between the SA and the SPA, but the large variation in SPA results 
reflect the inability to predict the SPA outcome of an individual case. In the presence of 
a normal SA, the SPA was most often positive and in case of a severely impaired SA the 
SPA was negative in the majority of men. When only one semen characteristic was 'not 
good' the SPA result could not be predicted. 
The potential of the SPA in screening defects of sperm function which are normally 
not detected by routine SA, has been evaluated by a number of investigators. Un-
fortunately, it appears that there is no concensus on the predictive value of the test.6·8·15-
19
 Most investigators could not demonstrate a dependence of sperm penetration rates 
upon sperm concentration, motility and morphology.8·9·15-17 Cohen et al.18 observed a 
low but significant correlation between the percentage of normal spermatozoa and the 
SPA. Rogers et al.19 also showed that the SPA correlated best with sperm morphology. 
Wickings et al.23 found no difference in penetration rates between infertile men with 
normal and with abnormal seminal parameters. The degree of correlation reported may 
depend on the selection of the group of samples. 
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Reduced penetration rates can be a consequence of the functional incompetence of the 
spermatozoa or can be due to reduced normal, motile sperm numbers.24 In case of a 
negative SPA and an abnormal SA it is not possible to determine whether the 
spermatozoa failed to penetrate due to an intrinsic defect of sperm function or due to a 
reduced sperm number. 
6.3 IMPORTANCE OF SPERM MOTILITY AFTER 
PRE-INCUBATION IN THE INTERPRETATION OF THE 
ZONA-FREE HAMSTER OVUM SPERM PENETRATION 
ASSAY 
(Partly published in FertU Steril 47: 456-459,1987) 
6.3.1 Introduction 
There is no standardised procedure for the performance of the SPA. The outcome of the 
SPA is dependent on many variables in the technical performance of the test.5 The 
preincubation time of sperm is an extremely important variable in the procedure.25 
During the preincubation period the spermatozoa have to undergo capacitation and 
acrosome reaction as mentioned previously. 
A crucial factor in the interpretation of the outcome of the SPA is the survival and 
motility of the spermatozoa after the in vitro capacitation process, just before they are 
added to the hamster oocytes. 
The study in this chapter evaluates the influence of the motility after preincubation 
on the results of the SPA for both normal and abnormal semen samples. 
63.2 Material and methods 
The study group consisted of 220 men as described previously (6.2.2.1). SA and SPA 
were carried out as described in 6.2.2.2 and 6.2.2.3, respectively. Additionally the 
motility grade after the preincubation period of the spermatozoa was determined in the 
same way as the motility grade was scored in the routine SA. 
6.3.3 Results 
After the preincubation period of 18 to 20 hours the spermatozoa of 69 semen samples 
were immobile or moved poorly or moderately. A motility grade of 4 or more was seen 
in 151 ejeculates after washing and preincubation. Initially 196 males had a motility 
grade of 4 or more (Table VI.4). In 53 of these the motility was impaired to a grade 3 or 
less after washing and preincubation. Of the 24 semen samples with an insufficient 
initial motility 8 improved after washing or during the preincubation period. In 159 
cases the motility grade remained unchanged. 
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Table VI.4 Influence of washing and preincubation on the 
motility grade 
Motility grade After preincubation 
<4 £4 
Before <4 16 8 
preincubation ¿4 53 143 
When the motility after capacitation in vitro was compared with the results in the SPA, 
for both the samples with an abnormal and those with a normal spermiogram, 
statistically significant differences in positive SPAs were found between samples with a 
normal and with an abnormal motility after preincubation (table VI.5). 
Table VI.5 Frequency of positive SPAs in relation to the motility 
afterpreincubation for 220 semen samples with a normal or abnormal 
routine semen analysis 
Motility grade 
after preincubation SA abnormal SA normal 
Immotile-Moderate 18/54* 33% 7/15** 47% 
(<4) 
Fairly good-ExceUent 42/62* 67% 82/89** 92% 
(>4) 
* ρ = 0.001 
** ρ = 0.003 
The mean penetration rates and the standard deviations for the semen samples of the 
four groups are shown in table VI.6. The highest penetration rates were found when the 
motility grade after preincubation was >4. 
Of the 220 males, 89 had a completely normal routine SA and a sufficient motility 
after preincubation. Of these 89 men only 7 had a negative SPA score. 
Table VI.6 Mean penetration rate (% ± SD) in relation to the 
motility after preincubation and the semen analysis for 220 
different semen samples 
Motility grade 
after preincubation SA abnormal SA normal 
Immotile-Moderate 10.8 ± 22.6 26.7 ± 36.8 
(<4) 
Fairly good-ExceUent 33.5 ±33.9 51.7 ±36.3 
(>4) 
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The strength of the relation between the classical semen parameters and the motility 
grade after preincubation (expressed by the contingency coefficient) is given in table 
VI.7. 
Table VI.? Contingency coefficients of the semen para-
meters of 220 males in relation to the motility grade after 
preincubation 
Semen characteristic Contingency coefficient of the 
motility grade after preincubation 
Density 0.326 
% Motility 0.216 
Motility grade (SA) 0.257 
Morphology 0.328 
Density and morphology showed the highest correlation with the motility grade after 
preincubation. 
The relation between the motility grade after preincubation and the result of the SPA 
for two definitions of positive SPA (more than 0% and more than 15%) is expressed by 
the contingency coefficients. The highest contingency coefficient was found when the 
lower limit of a positive SPA was 1% (contingency coefficient 0.414) in comparison to 
a lower limit of 16% (contingency coefficient 0.376). Both for the definition 'more than 
0%' and 'more than 15%', the motility grade after preincubation showed the strongest 
correlation with the SPA score in comparison to the classical semen characte-
ristics.(Table VI.3) 
6.3.4 Discussion 
The outcome of the SPA is influenced by the protocol used to perform the assay. One of 
the most important of these is the preincubation period. During this period the capacita-
tion and acrosome reaction, both essential conditions for penetration of the oocyte, must 
occur.4·12 During the washing procedure and/or the preincubation period the motility of 
the spermatozoa can change. 
This study showed a statistically significant decrease in the number of positive SPA 
scores when the motility grade of the spermatozoa after the preincubation period was 
<4, compared with semen samples with a motility of >4 after preincubation. Motility 
after preincubation showed a stronger correlation with the SPA than any of the other 
classical semen characteristics. 
There is no concensus about the ideal preincubation period, possibly because the time 
required for capacitation is different for each individual.5·12 The preincubation period of 
the 220 samples of this study was 18 to 20 hours, to provide every ejaculate ample time 
to capacitate. Some authors have reported better results in the SPA after an incubation 
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time of 19 to 20 hours, compared with a shorter period of 6 to 7 hours.25·26 In another 
study, no difference in penetration rate was noted when sperm was left to capacitate 
either for 5 to 7 hours or for 18 to 20 hours before insemination.23 In contrast, Zausner-
Guelman et al.17 reported a nearly opposite result: sperm preincubatcd for 2 to 3 hours 
produced higher penetration levels than did those preincubatcd for 17 to 24 hours. In the 
same study a positive correlation existed between sperm survival at the end of the 
preincubation period and the SPA score. This is in agreement with our study. 
Some studies have indicated that the outcome of the SPA is influenced by the 
concentration of motile spermatozoa in the incubation medium.27·28 Aitken et al.29 
demonstrated in a group with unexplained infertility that 91% of the positive SPAs were 
correctly identified by the postcapacitation movement characteristics. Cohen et al.18 
could not demonstrate a significant correlation between the motility of the sperm cells 
at the end of the preincubation period and fertilisation percentage of the hamster 
oocytes. Gould et al.30 observed a decline in sperm motility during preincubation, but 
this had no influence on the result in the SPA. To avoid possible false-negative SPAs 
due to insufficient density of motile spermatozoa, it has been suggested to standardise 
the SPA for a fixed concentration of motile spermatozoa.31 
From this study it can be concluded that insufficient motility after preincubation of 
the spermatozoa is an important factor determining the result of the SPA. The motility 
after preincubation must be taken into account when the SPA score is negative. 
6.4 THE INFLUENCE OF WHITE BLOOD CELLS AND 
PERCOLL WASHING ON THE ZONA-FREE HAMSTER 
OVUM SPERM PENETRATION ASSAY 
6.4.1 Introduction 
Surprisingly, the seminal fluid is supposed to be a sub-optimal environment for sperma-
tozoa, especially when the semen plasma contains white blood cells.32 Recently it has 
been reported that the presence of inflammatory cells in the semen impairs the penetra-
ting ability of spermatozoa both in human oocytes and in zona-free hamster 
oocytes.33·34 
Various methods are described to separate spermatozoa from other components in the 
semen.35-38 Gorus and Pipelcers39 first introduced the use of Percoli to isolate human 
spermatozoa from semen and other seminal components and to fractionate these 
spermatozoa according to their relative motility. It has been reported that the yield of 
spermatozoa with this method is at least as good as any other separation technique.40 
The Percoli centrifugation method has advantages in terms of recovery rate.41 Forster et 
al.42 examined the influence of the Percoli separation procedure on sperm motility, 
morphology and sperm function using the zona free hamster ova sperm penetration 
assay (SPA). They found an enhanced SPA-score after Percoli centrifugation in 
comparison with the conventional sperm washing method with modified BWW. 
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The aim of this study was to investigate the influence of Percoli layer centrifugation on 
the survival rate after overnight preincubation and the hamster ova penetration rate of 
semen samples with and without white blood cells (WBCs). 
6.4.2 Materials and methods 
The study group consisted of 291 men of infertile couples. Only one semen sample of 
each man was admitted to the study. 
The number of WBCs was counted in the Makler counting chamber with the use of 
phase contrast microscopy (magnification lOOx) for discrimination between WBCs and 
immature germ cells. The upper limit for WBCs in a normal semen sample is 
IxlOfymL. 
Two methods were used for sperm preparation: the first method as described in 
6.2.2.3, the В WW procedure, and by the second method the sample was centrifuged on 
a 80% Percoli layer after liquefaction and than washed with BWW. 
6.4.3 Results 
No white blood cells were seen in 202 semen samples; 151 of these were washed with 
modified BWW and 51 with Percoli. Of the 89 semen samples which contained white 
blood cells, 62 were washed with modified BWW and 27 with Percoli. WBCs were 
never seen in the specimen after centrifugation of the semen on a 80% Percoli layer. 
The presence of white blood cells in the ejaculate had a negative influence both on 
the percentage of men with a positive SPA-score and on the penetration rate (table VI.8, 
p<0.05). 
No statistically significant differences were seen between the BWW washing proce­
dure and the Percoli centrifugation, either in the percentage of men with a positive SPA, 
nor in the penetration rate. This observation was independent of the presence of leuco­
cytes in the ejaculate before centrifugation. 
Table Vl.fi Percentage of semen samples with a positive SPA-score and mean 
penetration rate (%Pen) related to the presence of white blood cells (WBCs) 
before centrifugation and the method of semen washing 
Modified BWW Percoli 
Positive SPA %Pen Positive SPA %Pen 
WBCs absent 72% (109/151) 40 61% (31/51) 30 
WBCs present 58% (36/62) 21 52% (14/27) 25 
The mean penetration rate of semen samples containing white blood cells when 
centrifuged on a Percoli layer was not different from semen samples washed with 
BWW. 
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A strong correlation exists between the motility after preincubation and the SPA 
result.(see 6.3). The motility after preincubation in relation to the presence of WBCs is 
given in table VI.9. Both in the absence as well as in the presence of white blood cells, 
modified BWW-washing gave a slightly better motility after preincubation than the 
Percoll-method (Table VI.9). 
Table VI.9 Percentage of semen samples with motility after pre­
incubation >4 related to the presence of white blood cells (WBCs) 
before centrifugation and the method of semen washing 
Modified BWW Percoli 
WBCs absent 71% (107/151) 65% (33/51) 
WBCs present 66% (41/62) 59% (16/27) 
In the second part of the study, ejaculates of 12 men were collected. Half of the eja­
culate was submitted to the modified BWW washing method and the other half to the 
Percoli centrifugation method (table VI. 10). 
In 5 ejaculates a minimum of 1 χ lOfymL leucocytes were present; 3 had a negative 
SPA-score both after the modified BWW and the Percoli method and 2 had a positive 
score. These samples showed a slightly higher penetration rate after Percoli washing. 
Of the 8 semen samples without leucocytes, 2 had a negative SPA both after BWW 
and Percoli; 4 showed a slight but not significant increase of the penetration rate after 
Percoli washing. In one semen sample the SPA was negative after BWW washing and 
positive after Percoli centrifugation (penetration rate 33%). In contrast, in one ejaculate 
the penetration rate decreased from 100% to 31% after Percoli washing, despite a very 
good motility after the preincubation period. 
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Table VI. 10 Routine semen characteristics, motility after preincubation and penetra­
tion rate of 13 semen samples which partially were submitted to the modified В WW 
washing method and partially to the Percoli centrifugation method 
Pat Vol Count Leuco %Mot Mot Abn Mot after preinc %Penetration 
nr mL xlO6/ xlO6/ Grade Forms В WW Percoli BWW Percoli 
220 
225 
226 
234 
235 
247 
254 
258 
259 
285 
288 
295 
302 
5.7 
4.4 
3.3 
5.3 
4.5 
3.1 
6.0 
3.4 
4.0 
2.5 
1.2 
3.4 
5.7 
mL 
22 
20 
77 
32 
49 
60 
54 
64 
135 
13 
40 
75 
61 
mL 
_ 
3 
5 
6 
-
-
-
-
-
1 
1 
-
_ 
50% 
100% 
100% 
30% 
100% 
100% 
100% 
100% 
100% 
100% 
20% 
50% 
30% 
6 
5 
4-5 
3-4 
6 
5 
5 
5 
5 
4 
4 
5 
4 
% 
49 
45 
50 
47 
40 
35 
32 
44 
25 
37 
62 
60 
46 
30% 
100% 
40% 
10% 
100% 
100% 
100% 
10% 
100% 
10% 
10% 
10% 
30% 
4 
2 
5 
5 
6 
5 
6 
4 
6 
2 
2 
2 
3 
10% 
10% 
100% 
100% 
70% 
100% 
30% 
100% 
10% 
10% 
50% 
40% 
2-3 
5 
6 
1 
6 
6 
6 
5 
6 
2 
3 
5 
5 
0% 
0% 
29% 
0% 
30% 
0% 
55% 
27% 
100% 
0% 
20% 
0% 
0% 
0% 
0% 
33% 
0% 
50% 
10% 
70% 
44% 
31% 
0% 
30% 
0% 
33% 
6.4.4 Discussion 
Previous studies have shown that seminal plasma affects the fertilising capacity of 
spermatozoa, probably because semen plasma contains decapacitation factors.32 In vivo 
the separation of spermatozoa from seminal plasma is one of the most important 
functions of cervical mucus, and cervical mucus may act as a bacteriological filter.43 
There is no consensus about the method of this separation in vitro.44 
This study examined the effect of two different sperm washing procedures on the 
ability of human spermatozoa to fertilise zona-free hamster ova, with special emphasis 
on the presence or absence of white blood cells in the ejaculate. We confirmed previous 
reports that the presence of white blood cells in semen has a negative effect on sperm 
function.33·45-47 The results in the SPA for samples with at least 1 χ IO6 WBCs/mL 
were significantly lower than without WBCs. 
In spite of the removal of the leucocytes the semen samples washed with Percoli had 
less frequently a positive SPA than the samples washed with modified BWW. 
Furthermore, Percoli did not improve the motility grade after the preincubation period 
at the time of combination with the hamster oocytes, either in the absence nor in the 
presence of WBCs in the ejaculate. This is in in agreement with the investigation of 
Berger et al.4 1 who found that the velocity of sperm was not significantly enhanced 
after the Percoli separation technique, but the ability to penetrate zona-free hamster ova 
was increased in this study. In contrast, the study of Pousctte et al.,48 reported that in a 
group of fertile men the Percoli separation technique improved the progressive motility 
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index. However, when samples from patients with abnormal semen profiles were 
separated in this way, the degree of improvement was much more variable. 
In order to examine the effect of Percoli washing both on motility after preincubation 
and on the results in the SPA, 13 ejaculates of different men were partially submitted to 
the modified BWW washing procedure and to the Percoli centrifugation method. Only 
in two semen sample the penetration rate increased from a negative result to positive 
with the Percoli procedure. In the other cases a negative SPA score remained negative 
and a positive result remained positive. 
Although Percoli centrifugation can remove the WBCs from the semen, our results 
indicate that the white blood cells have had their deterious effect on the spermatozoa 
already. This is in agreement with the study of Rogers et al.,49 who demonstrated that 
the effect of seminal plasma on spermatozoa could not be reversed by subsequent wash-
ing. Prolonged exposure of the spermatozoa to seminal plasma gave a reduction of 
fertilisation. 
Our study showed no advantage of the Percoli washing procedure on the SPA results 
and the motility after preincubation. 
6.5 COMPARISON OF THE ZONA-FREE HAMSTER 
OVUM SPERM PENETRATION ASSAY AND THE SPERM 
PENETRATION METER TEST ACCORDING TO 
KREMER 
6.5.1 Introduction 
An essential part of the investigation of an infertile couple is the evaluation of the inter-
action between spermatozoa and cervical mucus. The only in vivo test for this purpose 
is the postcoital test or Sims-Huhner test In vitro the penetration and migration of sper-
matozoa into cervical mucus can be investigated by the sperm penetration meter (SPM) 
test according to Kremer.1 The performance of spermatozoa in such a test depends on 
functions of the sperm cells as well as on the properties of the mucus. A great advantage 
of the SPM-test above the postcoital test is the possibility to carry out crossed SPM-
tests to determine whether the cause of a negative homologous SPM-test is determined 
by the semen or the cervical mucus. The SPM-test produces objective data about the 
semen sample: it is also a functional test in which spermatozoa demonstrate their ability 
to migrate into cervical mucus and to survive. 
The SPA measures the ability of spermatozoa to penetrate the oocyte membranes. In 
this chapter these two functional tests to determine sperm quality are compared. 
94 
6.5.2 Materials and methods 
The SPM-test and the SPA were performed in 140 different semen samples of different 
men of infertile couples visiting the outpatient department for Gynaecologie Endo­
crinology and Infertility. 
The SPM-test was carried out with human preovulatory cervical mucus of macro-
scopically good quality. A round glass capillary tube was filled with cervical mucus and 
placed in a reservoir containing the patient's semen. At a magnification of 100 χ the 
number of spermatozoa per visual field at a certain distance and at a certain time were 
recorded. The results of the SPM-test were judged and scored with the use of the SPM 
score according to Roumen,50 a simplification of the original scoring system of Kremer. 
(table VI. 11) 
The SPA was performed as described in 6.2.2.3. 
Table VI.11 The SPM-score according to Roumen 
Judgement 
Good 
Sufficient 
Moderate 
Bad 
Negative 
Score 
5 
4 
3 
2 
1 
Minimal no of 
1 
or. 10 
1 
1 
1 
0 
sperm On distance 
(cm) 
5 
5 
5 
3 
<3 
<3 
After time 
(hrs) 
1/2 
2 
2 
2 
2 
2 
6.5.3 Results 
The score of the SPM-test was compared with the chance of a positive SPA-score and 
with the penetration rate in the SPA. Both correlations are presented in figures 6.1 and 
6.2. 
Of the 140 samples included in this study, 23 had a SPM-score of 2,20 a SPM-score 
of 3,34 had a SPM-score of 4 and there were 63samples with a SPM-score of 5. 
Out of the 23 samples with a SPM-score of 2, 6 penetrated at least one egg in the 
SPA giving a chance of a positive SPA of 0.26; of the 20 samples with a SPM-score of 3 
again 6 had a positive SPA; of the 34 samples which scored moderately well (4) in the 
SPM, 25 scored positive in the SPA and 48 of the 63 samples with a SPM score of S had 
a positive SPA. Figure 6.1 depicts the relation between the SPM-score and the 
frequency of semen samples which penetrated at least one hamster oocyte in the SPA 
(p=0.005). 
In figure 6.2 the significant correlation between the SPM-score and the percentage of 
eggs penetrated in the SPA is shown. However, in each of the four groups of SPM-
scores the range of penetration rates was 0 -100%. 
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Figure 6.1 Relation between the SPM score according to Roumen and the frequency 
of males with a positive SPA for 140 different semen samples 
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Figure 6.2 Relation between the SPM score according to Roumen and the 
penetration rate in the SPA for 140 different semen samples (Mean ± SD) 
6.5.4 Discussion 
The SPM-test and the SPA are qualitative tests which contribute in diagnosing the ferti­
lity potential of men. Both laboratory tests arc objective assays to simulate processes 
occuring in vivo, namely migration of human spermatozoa into cervical mucus and pe­
netration of the oocyte membrane. 
The SPM-test according to Kremer depends on the quality of both the cervical mucus 
and the sperm cells. The subject of this study was the function of the spermatozoa, 
therefore the quality of the cervical mucus was standardised. 
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Positive correlations were observed between the SPM-score and both the percentage of 
men with a positive SPA and the penetration rate in the SPA. Men with a SPM-score of 
4 or 5 (sufficient or good) had significantly more often a positive SPA in comparison to 
men with a SPM score lower than 4. The penetration rate showed a gradual increase 
from 14.0% at a SPM-score of 2 to 39.9% when the SPM-score was good (=5). But in 
all the 4 groups penetration rates ranged from 0% (negative) to 100%. The outcome of 
an individual SPA could not be predicted accurately by the SPM-test of the same 
person. This conclusion is also drawn from the study of Takemoto et al.,51 which 
suggests that the properties of the sperm cells critical to the two types of penetration are 
different. Hirschel et al.52 compared in a group of 30 patients the CMPT (a modified 
SPM-test) and the SPA and found no correlation between these tests, suggesting that the 
CMPT and the SPA detect variables which contribute independently to infertility. 
A significant relationship between the PCT and the SPA was found in a study of 
Soûles et al.,53 but the range of the individual values was too large to recommend 
exclusion of either test as part of a complete infertility evaluation. Controversely, other 
investigators54 found a good correlation between the SPA and the ability of spermatozoa 
to penetrate cervical mucus (r=0.623, p<0.01). It is suggested that spermatozoa unable 
to penetrate preovulatory cervical mucus were usually also unable to fertilise the human 
oocyte.55 
The common factor influencing cervical mucus penetration and hamster egg 
penetration may be the specific motility patterns of the spermatozoa. Motility is a 
critical factor determining both the fertilising capacity of the spermatozoa10·28 and their 
ability to migrate through cervical mucus.35 The SPM evaluates indirectly the motility 
of the spermatozoa. A negative SPM may reflect a defective sperm function which can 
also manifest itself in a negative SPA. This study indicates that both assays measure 
different sperm properties, and that both tests contribute separately to the total infertility 
investigation. 
6.6 SENSITIVITY AND SPECIFICITY OF THE ZONA-FREE 
HAMSTER OVUM SPERM PENETRATION ASSAY IN 
RELATION TO HUMAN IN VITRO FERTILISATION 
6.6.1 Introduction 
The right selection of couples for admission to an in vitro fertilisation (IVF) and embryo 
transfer (ET) program is not only the first but also a very important step in the 
procedure. The screening of the male partner usually relies upon the results of the con-
ventional SA, which gives quantititive data about the semen. The SPA can give 
additional information on the ability of spermatozoa to capacitate and to penetrate the 
membrane of a zona-pellucida free oocyte. These are important conditions for fertilisa-
tion. There is no agreement in the literature, however, on the correlation between the 
SPA and male fertility.8·9·15-22 Furthermore, only few reports have been published about 
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the correlation between the SPA and human IVF. 5 · 5 6 - 5 9 These publications show con­
flicting results. 
In order to evaluate the prognostic value of the heterologous zona-free hamster ovum 
sperm penetration assay, the results of this test were compared with the fertilisation of 
human ova in a program for IVF and ET. The sensitivity and specificity of the SPA 
calculated from the data of this study are compared with those calculated from the data 
of other reports. 
6.6.2 Materials and methods 
6.6.2.1 Patients 
The patient group in this study consisted of 35 couples which entered the IVF program 
in Nijmegen between May 1984 and October 1985. In all couples IVF was applied to 
treat tubal infertility and there were no other abnormalities in their routine fertility 
investigation. All men had a normal SA previous to entering the IVF program. The 
criteria for normal SA values are given in 6.2.2.2. 
6.6.2.2 Collection and preparation of sperm 
The collection and preparation of the semen samples were almost identical for the SPA 
and for the IVF. In three cases the SPA and the IVF were carried out with aliquots of the 
same ejaculate. In all other men the SPA was performed approximately one month 
before the IVF. 
After liquefaction, the ejaculate was centrifugated on a 80% Percoli layer to remove 
abnormal spermatozoa and white blood cells, if present, and then washed twice with 
В WW medium. 
6.6.2.3 SPA 
The SPA was carried out as already described.(6.2.2.3) Only semen samples with a 
sufficient motility after preincubation (i.e. motility grade >4) were considered. When 
the SPA was negative, the SPA was performed a second time with another semen 
sample; the highest score was used for this study. A negative SPA means at least two 
negative SPAs on two different occasions. 
6.6.2.4 IVF 
Ovarian hyperstimulation was carried out with human menopausal gonadotrophin 
(HMG, Humegon®, Organon, Oss, The Netherlands) and human chorionic gonadotro­
phin (HCG, Pregnyl®, Organon, Oss, The Netherlands), or with the combination of 
clomiphene citrate (Clomid®, Gist-brocades, Rijswijk, The Netherlands) and HMG/ 
HCG. Follicular growth was monitored by ultrasound in combination with the 
determination of the ratio oestrogens to kreatinin in early morning urine. When the 
mean diameter of at least one follicle reached 14 mms and the oestrogen to kreatinin 
ratio exceeded 68, the HMG injections were discontinued. When three follicles or more 
reached a diameter of at least 15 mms and the oestrogen to kreatinin ratio exceeded 114, 
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HCG was administered. Approximately 34 hours after the HCG injection the oocytes 
were recovered by laparoscopy under general anaesthesia. Only those couples were 
admitted to the study in which the laparoscopy succeeded in obtaining mature oocytes. 
Semen was collected the same morning, centrifugated on a 80% Percoli layer and 
then washed twice with BWW medium. The spermatozoa were incubated for 4 to 
6 hours at 370C and were then inseminated with the oocytes in a concentration of 
25.000 to 50.000/mL. Evidence of fertilisation was the presence of cleavage to the 2-, 4-
or 8 cell stage 40 hours after insemination. When not two pronuclei were seen or when 
the oocytes showed no cleavage on the third day after the laparoscopy the IVF was 
judged as negative. 
6.6.2.5 Statistics 
The sensitivity is the ability of a test to identify a disease when it is indeed present60 It 
is reflected in the proportion of negative SPAs of those who failed to fertilise in the IVF. 
The specificity is the ability of a test to identify the absence of a disease when the 
disease is indeed absent It is shown in the proportion of positive SPAs of those who 
succeeded to fertilise human oocytes in the IVF. In a 2 χ 2 table the calculation of 
sensitivity and specificity of the SPA in relation to the outcome of IVF is shown. 
Table VI.12 Comparison of test results and clinical condition 
pos. disease neg. disease 
(= IVF neg.) (= IVF pos.) 
pos. test 
(= SPA 0%) a b 
neg. test 
(= SPA >0%) с d 
a 
Sensitivity: χ 100% 
a + c 
d 
Specificity: χ 100% 
b + d 
The positive predictive value of a test is the probability that a positive SPA result is 
accurate (IVF indeed negative). It is given in the formula a/a+b. 
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6.6.3 Results 
The results of the SPA and human IVF were compared in 35 couples (table VI. 13). 
Table VI.13 Contingency table for SPA and IVF results 
IVF negative IVF positive 
SPA negative 5 6 
SPA positive 4 20 
In 25 of patients concordant results were seen in the SPA and IVF. Five males had both 
a negative SPA and a negative human IVF. One of these 5 men again failed to fertilise 
his wife's oocytes on a second IVF attempt. In four cases false positive results (penetra-
tion in the SPA and no fertilisation of the human oocytes) were seen. Although the 
semen of 11 males repeatedly failed to penetrate hamster eggs 6 of them achieved 
fertilisation of their wife's oocytes which resulted in one pregnancy. 
The sensitivity of the SPA in this study was 56% (5/9), whereas the specificity was 
77% (20/26). The predictive value of a positive SPA was 83% (20 of 24), whereas 45% 
(5 of 11) of the men with a negative SPA were able to fertilise human eggs. 
The mean penetration rate for the hamster egg penetration assay was not significantly 
different for men who succeeded and men who failed to fertilise their wife's oocytes 
(51%vs45%). 
6.6.4 Discussion 
The main indication for IVF and ET is absent or impaired tubal function. The evalua-
tion of the male fertility in couples asking for IVF is usually based on the results of 
routine semen analyses. It is well accepted that some men despite normal semen para-
meters are infertile and that men with proven fertility can have a semen quality well 
below the normal range. The SPA is an additional parameter with which the sperm 
function can be assessed. 
The aim of this study was to investigate the validity of the SPA as a screening 
parameter for human IVF. The results of the SPA of males with normal routine semen 
characteristics were compared with the results of fertilisation and cleavage in a human 
IVF program. The data showed that the chance of succesfull fertilisation in the human 
IVF procedure is relatively high both for the males who had a positive SPA as for those 
with a negative SPA, 83% (20/24) and 55% (6/11), respectively. 
In some studies SPA- and IVF results were compared. The different studies on the 
SPA are difficult to compare due to the lack of standardisation of the technical perfor-
mance of this assay.5 Furthermore there is no consistency about the cut-off value of the 
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penetration rate to distinguish between a positive or a negative SPA. In our laboratory 
wc define a negative SPA as one without penetration, (see 6.2.2.3) 
The sensitivity of a test improves as the cutoff point is raised, but as a consequence 
specificity and predictive value are reduced. Despite the low limit for a positive SPA 
(0%), the specificity of this assay was less in this study compared to the specificity 
suggested by other investigators, (table VI.14) The sensitivity in this study, however, 
was higher than that of other investigators. 
Table ІЛ4 Validity of the SPA in relation to human IVF as assessed from the 
results of several authors 
Author 
Wolfetal.« 
Foreman et al.57 
Ausmanas et al.58 
Rogers5 
Maigalioth et al59 
This study 
η 
24 
37 
54 
29 
82 
35 
Lower limit 
of hamster egg 
penetration (%) 
10 
1 
15 
10 
20 
1 
Sensitivity 
0 
40 
33 
50 
50 
56 
Specificity 
89 
100 
73 
92 
100 
77 
In case of false positive results it is difficult to distinguish between impaired fertilising 
capacity of the spermatozoa or insufficient quality of the human oocytes, although in 
this study only IVF treatments were considered in which mature oocytes were collected. 
The sensitivity of the SPA which identifies the infertile men who are really infertile, 
was low in all studies. The proportion of men with a negative SPA who succeeded to 
fertilise one or more human oocytes does not justify the conclusion of some that the 
SPA is a useful screening parameter for IVF. Apparently the sperm cells can penetrate 
human oocytes more easily than they can penetrate hamster eggs. 
Because of the high incidence of false negative and false positive results of the SPA 
in relation to IVF results and also because of the impractability of the SPA, this assay 
seems to be of limited value in selecting male partners of particular couples seeking 
IVF/ET. In case of normal routine semen analysis the SPA is no addition or replacement 
to predict the success of human IVF. 
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6.7 GENERAL DISCUSSION AND CONCLUSIONS ON THE 
ZONA-FREE HAMSTER OVUM SPERM PENETRATION 
ASSAY 
Male infertility or subfertility can be caused by a variety of factors. In most of the cases 
the disorder can be confirmed by abnormalities of the semen. Routine SA is the most 
widely used method to assess a male's fertility potential. SA gives objective, quantita-
tive data. A clear prognosis of an individual case cannot be made on the basis of data 
obtained from the SA only. The functional competence of the spermatozoa is not 
necessarily reflected in the conventional semen profile. 
The SPM test and the SPA are two additional assays which evaluate the functional 
capacity of spermatozoa to penetrate cervical mucus and to penetrate the oocyte mem-
brane of a zona-pellucida free hamster egg. Both assays simulate processes that occur 
in vivo. In the SPM test both the quality of the cervical mucus and of the sperm cells are 
determined. By using donor cervical mucus the SPM test can provide objective 
information on the motility of the spermatozoa. 
The SPA is a laborious, not routinely used assay. This test simulates the last events 
just prior to the actual fertilisation. It is a great disadvantage that the technical 
procedure of the test is not standardised and that the outcome of the SPA is dependent 
on many variables. Before the sperm cells are exposed to the hamster eggs they have to 
undergo capacitation and acrosome reaction. This process takes place in vitro while the 
spermatozoa are washed from the semen plasma and preincubated in a medium. The 
results of the SPA are still equivocal, since sperm from some infertile men do penetrate 
zona-free hamster oocytes and, conversely, spermatozoa from some fertile men do not. 
The potential usefulness of this technique in fertility investigations requires further 
research. 
In this chapter studies are mentioned which describe the correlations between the 
SPA and other tests of semen quality and the influence of variables in the technical 
procedure on the results of the SPA. 
It was shown that a positive correlation existed between the parameters of the routine 
SA and the outcome of the SPA. A normal semen parameter gave a higher chance of a 
positive SPA and the more normal characteristics of the routine SA were seen, the 
higher the chance of a positive SPA. However, there were still a number of possibly 
infertile men who had a negative SPA despite normal routine SA. For an individual 
male it is not possible to predict the outcome of the SPA. 
When the motility after the preincubation period was taken into account in the 
interpretation of the SPA result, the number of men who scored negative in the SPA 
despite normal semen characteristics, decreased. Most likely only those men with 
repeatedly negative SPAs and sufficient motility after preincubation are really infertile. 
Another variable that influences the outcome of the SPA is the presence of white 
blood cells in the ejaculate. White blood cells have a negative effect on the fertilisation 
potential of spermatozoa. Centrifugation over a Percoll-layer of the semen sample can 
separate the spermatozoa from other components in the semen. However, the Percoli 
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washing procedure showed no advantage on the SPA results or on the motility grade 
after preincubation. It is likely that the white blood cells have exerted their effect on the 
spermatozoa before the washing procedure. 
The SPA and SPM test are both functional tests which determine sperm quality, in 
contrast with the routine SA which is a quantitative test. Positive correlations were seen 
between the SPM score and both the percentage of men with a positive SPA and the 
penetration rate in the SPA. Although a positive correlation between these two tests was 
observed, the range of the SPA result was too large to predict the outcome of the SPA on 
the base of the SPM score for an individual male. It is likely that the SPA and the SPM 
test measure different sperm properties, and that both tests contribute separately to the 
total fertility investigation of a man. Not all events of fertilisation can be examined by 
the SPA, but the existence of correlations between the outcome of the SPA and other 
aspects of sperm function including the penetration of cervical mucus, support the view 
that such tests may be of value in evaluating male fertility. 
The validity of the SPA was assessed by comparing the results of the SPA with the 
fertilisation of human oocytes in a program for IVF and ET. Both the sensitivity and the 
specificity of the SPA were relatively low to use this assay in selecting male partners for 
IVF and ET. 
The diagnostic value of the SPA has to be established further by performing carefully 
designed prospective studies. However, a major disadvantage of the evaluation of the 
fertility potential of an individual is the variability between ejaculates. 
Final conclusions: 
Neither routine SA, nor the SPA are absolute criteria for fertility. Routine SA is a 
quantitative- and the SPA is a qualitative-assay, but this latter assay does not examine 
the spermatozoon's ability to attach itself or to penetrate the zona pellucida. For this 
reason a positive result of the SPA should be interpreted with caution and such a result 
does not necessarily reflect that spermatozoa are capable to fertilise human oocytes in 
vivo or in vitro. 
A negative SPA should also be evaluated cautiously. Many non-standardised tech-
nical variables influence the outcome of the SPA. This means that a negative SPA does 
not always preclude the possibility of establishing a pregnancy, especially when the 
motility after the preincubation period is not optimal. 
The only valid indication for a SPA is unexplained infertility and sufficient motility 
after the preincubation period. Therefore the indications for the SPA should be limited 
to semen samples with sufficient motility after preincubation. 
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CHAPTER 7 
GENERAL DISCUSSION 
Approximately one in ten couples do not succeed in establishing a pregnancy after one 
year of unprotected intercourse. The number of couples seeking medical help for 
infertility is increasing. This stresses the importance of careful and accurate investiga­
tion of a couple's infertility. 
In many instances the main examinations and tests of the fertility workup program 
(see 1.3) reveal abnormalities as possible cause of infertility, and thereby indicating a 
rational therapy. The majority of infertile patients, however, do not have unequivocal 
findings and should be considered 'subfertile'. The routine fertility workup program of a 
number of couples reveal no abnormalities that can explain their infertility. This investi­
gation has been performed to study carefully the usefulness and completeness of some 
steps in the routine fertility workup program. 
The fertility potential of a couple depends on the normalities of three distinct steps in 
reproduction: 
1. Gamete production 
2. Fertilisation: gamete fusion 
3. Implantation 
In the previous chapters several aspects of these three steps have been studied and 
discussed. 
In the female an extensive investigation of the menstrual cycle has been performed, both 
in fertile and infertile patients. Frequent sampling of blood throughout one menstrual 
cycle provides information on cyclical patterns regulated through endocrine 
mechanisms. It was observed that prolactin does not demonstrate a definite cyclical 
pattern, but that the values of this hormone fluctuate throughout the cycle. Intermittent 
elevations of prolactin can be demonstrated, both in fertile and infertile women with 
either irregular or regular menstrual cycles. However, prolactin levels in the fertile 
group were only occasionally moderately above the level of normal prolactin 
concentrations, whereas in the infertile group several women showed more frequently 
clearly elevated prolactin concentrations. These patients can be considered as having 
transient hyperprolactinaemia. The frequent, rather high elevations of prolactin levels in 
infertile patients suggest interference of this hormone with their fertility potential. The 
way transient hyperprolactinaemia interferes with the regulation of the menstrual cycle 
is not clear. It is advisable to perform prolactin measurement in a fertility workup 
program in case of anovulation and/or amenorrhoea. This investigation stresses the need 
of measurement of prolactin at least twice to exclude transient hyperprolactinaemia, 
independent of whether the woman has a regular от irregular cycle. 
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The causes of menstrual irregularity are various and are mostly attended by anovulation. 
The infertile women of this study all demonstrated definite signs of ovulation. The 
endocrinological parameters of these women strongly indicated a mild or early form of 
PCOD. The PCO-syndrome is an ill defined disorder and a large clinical and biochemi-
cal variability is encountered in this disease. The main symptoms associated with PCOD 
are anovulation, signs of androgen excess and obesity. The endocrinological charac-
teristics of PCOD patients are elevated LH levels, normal or decreased FSH levels, 
resulting in an increased LH to FSH ratio, and elevated androgen and oestrogen values. 
The infertile women with irregular cycles in this investigation showed signs of 
inappropriate gonadotrophin secretion and elevated concentrations of androgenic ste-
roids. Especially the saliva androgens, which are supposed to represent the free propor-
tion of the hormone, were found to be elevated in many women with irregular cycles. 
This was also the case in the group with unexplained infertility. 
Despite ovulatory cyles, and even regular cycles, several endocrinological abnorma-
lities have been demonstrated in the infertile women. These findings indicate the 
usefulness of measuring gonadotrophins and saliva testosterone in all infertile women, 
also in those with ovulatory cycles. 
In studying the fertility of the male, SA is the most widely used and also easiest method. 
Several other, more recently developed tests are available to investigate the fertility 
potential of men, such as the SPM test and the SPA. All tests show a wide range of 
results, both in the fertile and in the infertile males. A large overlap exists in values 
obtained from fertile and infertile men. The results of the SA, SPM-test and SPA are not 
always in accordance with each other. Therefore it is likely that these tests measure 
different properties of the spermatozoa. The SA, SPM-test and SPA are complementary 
in the investigation of male fertility. 
It should be emphasized that the motility after the preincubation period of the 
spermatozoa, i.e. the period in which the spermatozoa have to undergo acrosome 
reaction and capacitation, is an important variable which determines the outcome in the 
SPA. Spermatozoa with an insufficient motility after preincubation are less capable to 
penetrate zona-free hamster oocytes. Therefore a negative SPA in combination with 
insufficient motility after preincubation does not per se reflect an intrinsic defect in 
sperm fertilising function. The results of the SPA and human IVF have been compared. 
The relatively low correlation between the SPA and the results in human IVF also 
stresses the need of a careful interpretation of the SPA results. The SPA is of limited 
value in measuring the fertilising ability of a semen sample. 
Implantation, the third event in normal reproduction, is difficult to investigate, without 
interfering with a pregnancy. One possibility to study this process is by determination of 
hCG, the hormone that is secreted at a very early stage by the conceptus, and that can be 
detected from the time of implantation onwards. Based on hCG determinations only, 
failure of implantation, early conceptual loss, is probably a normal event in the human 
reproductive process. By measuring hCG frequently in a prospective way both in fertile 
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women and in women with unexplained infertility, it was found that early conceptual 
loss is not likely to occur more often in infertile women, and is not a significant cause of 
unexplained infertility. Until now, no method is available to detect conceptual loss 
before implantation after normal in vivo fertilisation. Such a method would not only be 
helpful in detecting conceptual loss in infertile patients, but also in the investigation of 
successes and failures in human IVF and EX. 
The observation that 90% of the couples with unexplained infertility showed one or 
more subtle abnormalities emphasisis the importance of an accurate investigation of a 
couple's infertility. The diagnosis 'unexplained infertility' is only justified when also 
endocrinological abnormalities, such as transient hyperprolactinaemia and excess of 
androgen production, are excluded and an extensive investigation of the ejaculate, inclu-
ding at least three SAs and a SPA, has been performed. Human IVF would be of 
diagnosticai help in the evaluation of both follicular development, oocyte maturation, 
male spermatozoal quality and the ability of fusion of male and female gametes. 
Although it is tempting to attribute the described abnormalities to the cause of 
infertility, similar abnormalities have been observed in fertile couples. The difference 
between fertile and infertile couples involves the frequency of subtle abnormalities, and 
the combination of male and female abnormalities. An abnormality of one partner can 
probably be compensated by very good fertility parameters of the other partner of a 
couple. Furthermore, a suboptimal cycle or suboptimal ejaculate may subsequently be 
followed by a normal one. Abnormalities do not appear to be repetitive, this also 
explains why many women with either explained or unexplained infertility become 
pregnant spontaneously after a period of time. 
Conscientiously designed, prospective clinical trials arc necessary to study the need 
for treatment in cases with 'subtle endocrinological abnormalities'. The results of 
treatment should be compared to the frequency of pregnancies which are treatment-in-
dependent 
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SUMMARY 
Approximately ten percent of all couples trying to conceive do not succeed in 
establishing a pregnancy within one year. Both male and female factors and a 
combination of these can be responsable for the infertility. The standard investigation of 
a couple does not always reveal the cause of infertility, around five to ten percent of 
infertility is considered as unexplained. In detecting the cause of infertility the 
extensiveness of the fertility workup program is crucial. 
The studies presented in this thesis concern some newly developed diagnostic 
methods which are not included in the routine investigation of infertility. 
In the introduction the physiology of reproduction is reviewed. The process of 
normal fertilisation and implantation is described and the current concepts of the 
endocrinological events during the menstrual cycle and the role of androgenic steroids 
are summarised. An outline of the basic investigation of infertility is given. 
The first part of this thesis is a prospective, extensive study of the menstrual cycle. 
Three groups participated in the study: a group of 15 infertile women with irregular 
menstrual cycles, a group of 20 women with unexplained infertility and 20 assumed 
fertile women, who formed the control group. 
A description is given of the selection criteria, clinical characteristics and semen 
parameters of the groups, the schedule of blood and saliva collection and the immuno-
chemical procedures are presented and the statistical methods applied are explained. 
The endocrinological parameters of the women with irregular cycles and of those 
with unexplained infertility are compared with those of the control group. 
The LH levels and the LH/FSH ratios of the group with irregular cycles tended to be 
higher. Furthermore serum testosterone levels and saliva androgens were in a higher 
range in the women with irregular cycles. It is supposed that women with irregular but 
ovulatory cycles suffer from a mild or early form of PCOD. 
The LH concentrations of the women with unexplained infertility were higher during 
the follicular phase. The 17ß-oestradiol levels in serum as well in saliva were elevated, 
probably as aresult of the increased LH levels. The higher follicular LH levels can cause 
infertility by early luteinisation of the follicle or by a direct effect of LH on oocyte 
maturation. 
In all groups a large variation was seen in prolactin levels both within one subject as 
well as between subjects. In the infertile women some could be assigned as suffering 
from transient hyperprolactinaemia with frequently elevated prolactin concentrations 
during the study cycle. It is concluded that at least two prolactin determinations arc 
required in all infertile women. 
Eighteen of the 20 couples with unexplained infertility showed one or more subtle 
abnormalities in the female's hormonal secretory pattern and/or in the male's 
investigation of the ejaculate after extensive investigation. This suggests that one should 
be very careful with the diagnosis of unexplained infertility. 
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In the second part of the study hCG was measured during the luteal phase of 
20 assumed fertile women trying to conceive and in 20 women with unexplained 
infertility to detect conception at an early stage. Five clinical, ongoing pregnancies were 
observed in the fertile group. The range in first day of detection of hCG in these women 
was high. This indicates the need for very cautious interpretation of luteal hCG 
concentrations. Based on hCG determinations in the luteal phase clinically unrecog-
nised, early conceptual loss after implantation forms no major explanation for un-
explained infertility. 
The last part of the thesis deals with semen parameters, especially the zona-free hamster 
ovum sperm penetration assay. The relation between the SPA and the routine semen 
analysis was studied in a group of 220 males of infertile couples. Every normal semen 
parameter showed a statistically significantly higher chance to contribute to a positive 
SPA compared with an abnormal semen parameter. Furthermore, the more normal 
semen parameters in the SA were present, the more males showed a positive SPA. In the 
study group as a whole a significant correlation was demonstrated between the SA and 
the SPA, but the large variation in SPA results reflect the inability to predict the SPA 
outcome of an individual. 
This study demonstrated a statistically significant decrease inthe number of positive 
SPA scores when the motility grade of the spermatozoa after the preincubation period is 
insufficient Motility after preincubation showed a stronger correlation with the SPA 
than any of the other routine semen characteristics. 
The presence of white blood cells in the ejaculate had a negative effect on sperm 
function as reflected in the outcome of the SPA, From an experiment with centrifugation 
of the semen sample over a Percoli layer to remove white blood cells, compared with 
the routine BWW washing method, it was concluded that the white blood cells had their 
deterious effect on the spermatozoa already before separation. 
Positive correlations were observed between the SPM-score and both the percentage 
of men with a positive SPA and the penetration rate in the SPA. 
In an attempt to compare the SPA with the actual fertilisation in human in vitro 
fertilisation, the data showed that the chance of succesful in vitro fertilisation was 
relatively high both for the males who had a positive SPA as for those with a negative 
SPA. It was therefore concluded that the SPA cannot be used as a screening procedure 
for IVF. 
Carefully designed, prospective, basal and clinical investigations remain necessary to 
evaluate which factors do and which factors do not actually attribute to a couple's 
infertility. 
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SAMENVATTING 
Ongeveer 10% van de paren met kinderwens slaagt er niet in deze wens te vervullen 
binnen één jaar onbeschermde coitus. Zowel mannelijke als vrouwelijke factoren, of een 
combinatie, kunnen onvruchtbaarheid veroorzaken. Het standaard vruchtbaarheids-
onderzoek toont niet altijd de reden van de onvruchtbaarheid, naar schatting 5 tot 10% 
van de onvruchtbaarheid wordt beschouwd als onverklaard. De uitvoerigheid van het 
vruchtbaarheidsonderzoek is bepalend bij het opsporen van de oorzaak van de onvrucht-
baarheid. 
De studies in dit proefschrift hebben betrekking op enkele recent ontwikkelde diag-
nostische methoden die niet tot het standaard onvruchtbaarheidsonderzoek behoren. 
In de inleiding wordt een overzicht gegeven van de physiologie van de voortplanting. 
Het proces van de normale bevruchting en innesteling wordt beschreven en de huidige 
inzichten met betrekking tot de hormonale veranderingen van de menstruele cyclus en 
de rol van de androgene Steroiden worden besproken. Een samenvatting van het stan-
daard onvruchtbaarheidsonderzoek wordt gegeven. 
Het eerste deel van het proefschrift omvat een uitgebreid, prospectief onderzoek naar de 
menstruele cyclus. Drie groepen namen deel aan de studie: een groep van 15 onvrucht-
bare vrouwen met onregelmatige cycli, een groep van 20 vrouwen met onverklaarde 
onvruchtbaarheid en 20 vrouwen van wie werd verwacht dat zij vruchtbaar waren. Deze 
laatste groep vormde de controle groep. 
Er wordt een beschrijving gegeven van de selectie-criteria, de klinische kenmerken 
en de semen gegevens van de groepen, het schema van het verzamelen van de bloed- en 
speeksel monsters, de bepalingstechnieken en de statistische methoden. 
De hormonale gegevens van de vrouwen met onregelmatige cycli en die van de vrou-
wen met onverklaarde onvruchtbaarheid worden beiden vergeleken met de gegevens 
van de controle groep. 
De spiegels van LH en de LH/FSH ratio's van de groep met onregelmatige cycli 
vertoonden een tendens naar hogere waarden. Bovendien neigden de serum testosteron 
en speeksel androgenen spiegels naar hogere waarden bij de vrouwen met onregel-
matige cycli. Er wordt verondersteld dat vrouwen met onregelmatige, maar ovulatoire 
cycli leiden aan een milde of vroege vorm van het polycysteus ovarium syndroom. 
De LH concentraties van de vrouwen met onverklaarde onvruchtbaarheid waren 
hoger tijdens de folliculaire fase. De 17ß-oestradiol spiegels zowel in serum als in 
speeksel waren verhoogd, waarschijnlijk als gevolg van de toegenomen LH concen-
traties. De hogere LH spiegels kunnen onvruchtbaarheid veroorzaken door vroege 
luteinisatie of door een direct effect van LH op de rijping van de eicel. 
In alle groepen werd een grote spreiding gezien in de waarden van prolactine, zowel 
tussen de waarden van de cyclus van één vrouw, als tussen de waarden van de cyclus 
van verschillende vrouwen. Bij sommige vrouwen uit de onvruchtbare groepen kan de 
diagnose 'intermitterende hyperprolactinaemie' worden gesteld, omdat bij hen herhaal-
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delijk verhoogde prolactine concentraties werden gemeten gedurende de onderzoeks-
cyclus. Geconcludeerd wordt dat bij alle onvruchtbare vrouwen tenminste twee maal het 
prolactine gehalte moet worden bepaald. 
Bij 18 van de 20 paren met onverklaarde onvruchtbaarheid werden één of meerdere 
kleine afwijkingen gevonden in het hormonale patroon van de vrouw en/of in het 
uitgebreide semen onderzoek van de man. Dit duidt aan dat de diagnose Onverklaarde 
onvruchtbaarheid' zorgvuldig moet worden gehanteerd. 
In het tweede deel van het onderzoek wordt getracht zeer vroeg te bepalen of bevruch-
ting heeft plaats gevonden. HCG werd gemeten tijdens de luteale fase van de cyclus van 
20 vruchtbare vrouwen die zwangerschap nastreefden en 20 vrouwen met onverklaarde 
onvruchtbaarheid. In de vruchtbare groep werden 5 klinische, doorgaande zwanger-
schappen waargenomen. Er was een grote spreiding in het tijdstip waarop voor de eerste 
maal hCG kon worden gemeten in het serum van deze vrouwen. Dit toont aan dat hCG 
waarden in de luteale fase voorzichtig moeten worden geïnterpreteerd. Klinisch onhcr-
kend, vroeg verlies van de conceptus na de innesteling, gebaseerd op hCG bepalingen in 
de luteale fase, is geen belangrijke oorzaak voor onverklaarde onvruchtbaarheid. 
Het laatste gedeelte van het proefschrift gaat in op het onderzoek van semen, in het 
bijzonder de hamstereiceltest. De relatie tussen de hamstereiceltest en de traditionele 
semen analyse werd bestudeerd in een groep mannelijke partners van 220 onvruchtbare 
paren. Elke normale semen parameter afzonderlijk had een statistisch significant hogere 
kans om bij te dragen aan een positieve hamstereiceltest dan een abnormale semen para-
meter. De kans op een positieve hamsteeiceltest nam toe naarmate meer normale semen 
karakteristieken werden gezien bij de semen analyse. In de onderzoeksgroep als geheel 
werd een significante correlatie aangetoond tussen de semen analyse en de hamster-
eiceltest, maar de grote spreiding in hamster eicel test uitkomsten weerspiegelde het 
onvermogen van de semen analyse om de uitkomst van de hamstereiceltest van een 
bepaalde persoon te voorspellen. 
Deze studie toont aan dat het aantal positieve hamstereiceltesten significant afneemt 
indien de beweeglijkheid van de zaadcellen na de pre-incubatietijd onvoldoende is. De 
beweeglijkheid van de zaadcellen na de pre-incubatietijd had een sterkere correlatie met 
de hamstereiceltest dan elk van de andere traditionele semen karakteristieken. 
De aanwezigheid van witte bloedcellen in het ejaculaat had een negatief effect op de 
funktie van de zaadcellen, zoals gemeten in de hamstereiceltest. Uit een onderzoek 
waarbij centrifugatie van het zaad monster met een Percoli oplossing, om eventuele 
witte bloedcellen te verwijderen, werd vergeleken met de traditionele BWW methode, 
werd geconcludeerd dat de witte bloedcellen hun negatief effect op de spermatozoa al 
hadden uitgeoefend voor de scheiding. 
Positieve correlaties werden aangetoond tussen de SPM-score en zowel het percen-
tage mannen met een positieve hamstereiceltest als de penetratie graad in de hamster-
eiceltest. 
116 
In een poging om de hamster eicel test te vergelijken met de feitelijke bevruchting in in 
vitro fertilisatie bij mensen, werd uit de gegevens van 35 paren aangetoond dat de kans 
op succesvolle in vitro fertilisatie relatief hoog was, zowel voor de mannen met een 
positieve als met een negatieve hamstereiceltesL Daarom werd geconcludeerd dat de 
hamstereiceltest geen goede selectie methode is voor in vitro fertilisatie. 
Zorgvuldig opgezette, prospectieve, basale en klinische onderzoeken blijven noodzake-
lijk voor de evaluatie van de factoren welke wel en welke niet feitelijk bijdragen aan de 
onvruchtbaarheid van een paar. 
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ABBREVIATIONS 
АСТН 
Andr 
ВВТ 
BWW 
Cor 
DHEA 
DHEAS 
ET 
FAI 
FSH 
GnRH 
hCG 
hGH 
HMG 
hPL 
ШМА 
IRMA 
IRP 
IS 
IVF 
LH 
LHRH 
MAP 
MAR 
OE2 
PCOD 
PRL 
Prog 
RIA 
SA 
SD 
SEM 
170HP 
SHBG 
SPA 
SPM 
T4 
Test 
WBC 
AdrenoCorticoTrophic Hormone 
Androstenedione 
Basal Body Temperature 
Biggers-Whitten-Whittmgham medium 
Cortisol 
DeHydroEpiAndros terme 
DeHydroEpiAndrosterone Sulphate 
Embryo Transfer 
Free Androgen Index 
Follicle Stimulating Hormone 
Gonadotrophin Releasing Hormone 
Human Chorionic Gonadotrophin 
Human Growth Hormone 
Human Menopausal Gonadotrophin 
Human Placental Lactogen 
ImmunoEnzyMetric Assay 
ImmunoRadioMetric Assay 
International Reference Preparation 
International Standard 
In Vitro Fertilisation 
Luteinising Hormone 
Luteinising Hormone Releasing Hormone 
Motility After Preincubation 
Mixed Antiglobulin Reaction test 
17ß-oestradiol 
Polycystic Ovarian Disease 
Prolactin 
Progesterone 
Radio ImmunoAssay 
Semen Analysis 
Standard Deviation 
Standard Error of the Mean 
17a-OH-Progesterone 
Sex Hormone Binding Globulin 
Sperm Penetration Assay 
Sperm Penetration Meter test 
Thyroxine 
Testosterone 
White Blood Cell 
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Stellingen behorende bij het proefschrift 
THE INFERTILE COUPLE: 
SOME CYCLE AND SPERM CHARACTERISTICS 
door 
Bernardina Petronella Johanna van Duren 
STELLINGEN 
1 Bij iedere vrouw die een fertiliteitsonderzoek ondergaat, moet de prolactine concen­
tratie minstens twee maal worden bepaald. (dit proefschrift) 
2 Het speeksel testosteron gehalte is een waardevolle parameter in het fertiliteits­
onderzoek van de vrouw. (dit proefschrift) 
3 Het verrichten van een hamstereiceltest is alleen zinvol indien de motiliteit van de 
spermatozoa na voorbewerking voldoende is. (dit proefschrift) 
4 Het dichterbij brengen van de zaadcel bij de eicel betekent niet noodzakelijk dat de 
kans op zwangerschap toeneemt 
5 Psychogene infertiliteit is niet bewezen. 
6 Aangezien Homerus in παρευναζομαι geen trema gebruikt is het onlogisch dat in 
dyspareunie wel te doen. 
7 Bevallen is een goed begin van de opleiding tot vrouwenarts. 
8 Stellingen verhogen niet de wetenschappelijke waarde van een proefschrift. 

